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Promising treatments of many brain diseases are often thwarted due to their in-
ability to cross the blood-brain barrier. Convection-enhanced drug delivery (CED)
uses direct infusion of drug-containing solutions into tissue to circumvent the blood-
brain barrier. The aim of this thesis was to combine models of transport in porous
media with microfabricated devices to develop novel methods for controlling the
distribution of infused drugs. We used a poroelastic model of the brain to explore
the eﬀect of infusion induced dilation on transport. We calculated that during in-
fusions at ﬂow rates greater than one microliter/minute, the eﬀective pore size of
the extracellular matrix was doubled by dilation from approximately ﬁfty nanome-
ters to one-hundred nanometers. A computational ﬂuid dynamic model of the rat
brain determined the perturbation of the ﬂow ﬁeld between white and gray matter.
We found no further perturbation of the ﬂow ﬁeld when the ratio of permeabilities
between white and gray matter exceeded one-hundred. The results of our models
suggest that the material properties of a targeted tissue region dictate the trans-
port of infused solutions. To better control and manipulate drug distribution we
developed a novel microﬂuidic platform for delivering drug-solutions at ﬂow rates
relevant for CED. The microﬂuidic devices consisted of parylene channels with
a cross-section area of ﬁfty microns by ten microns on a silicon structure with across-sectional area of one-hundred microns by one-hundred microns. These probes
were tested in the normal rat brain and demonstrated performance advantages over
standard needles, including no channel occlusion and attenuation of backﬂow. We
expanded on the simple single channel device to implement more advanced strate-
gies using multiple channels. A two-channel device was fabricated for infusing
an enzyme or mannitol solution prior to infusing polystyrene nanoparticles. By
pre-treating the targeted tissue region with enzymes or mannitol we increased the
eﬀective pore size of the extracellular matrix which resulted in a doubling of the
distribution volume of nanoparticles.BIOGRAPHICAL SKETCH
Keith Neeves was born and raised Colorado Springs, Colorado. He received an In-
ternational Baccalaureate degree from Palmer High School in 1996 and a Bachelor
of Science in Chemical Engineering from the University of Colorado at Boulder
in 2000. Keith has lived and studied in many places including Southeast Asia,
the Middle East, and Latin America. As a graduate student he was awarded fel-
lowships from the Keck Foundation, Epilepsy Foundation of American, and the
National Science Foundation. The School of Chemical and Biomolecular Engi-
neering at Cornell recognized him with awards for both teaching (TA of the Year)
and research accomplishments (Hooey Award).
iiiTo my role models, my parents, Linda Resnick and Phillip Neeves
ivACKNOWLEDGEMENTS
I had the opportunity to work under three excellent advisors who were integral in
my development as a scientist-Bill Olbricht, Mark Saltzman, and Mike Isaacson.
Scott Retterer and Andrew Spence greatly inﬂuenced the early part of my graduate
career both as mentors and friends. Conor Foley made invaluable contributions
toward the understanding of gel invagination and was an entertaining travel partner
from New Haven to Prague. The CNF staﬀ were an critical resource throughout,
especially Rob Ilic, Jim Clair, Mike Guillorn, and Mike Skvarla. I would like to
thank everyone in the Saltzman group at Yale for being so helpful and patient,
but particularly Catherine Lo, Andrew Sawyer, Tarek Fahmy, Jason Park, and
Matt Brennan. Dave Putnam gave great me career advise, but more importantly
gave me a place to sit. Thanks to the Putnam group for putting up with me for
a few years. Finally, my most rewarding experience at Cornell was as a teacher
because my students always taught me so much more than I taught them-Mrs.
Guilford’s 3rd grade class at Candor Elementary, Sarah Brumberg’s chemistry
students at Lehman Alternative Community School, Patricia Carroll’s chemistry
and physics classes at Newark Valley High School, ChemE 324 Heat and Mass
Transfer (classes of 2003 and 2004), and Masters of Engineering students (Devon
Murphy, Rob Ferris, Shwetali Sawant, Tandis Movasagh, Yuewai-Evonne Fung).
This work was supported by the National Institutes of Health Grant NS-045236.
This work was performed in part at the Cornell NanoScale Facility, a member of
the National Nanotechnology Infrastructure Network, which is supported by the
National Science Foundation Grant ECS 03-35765.
vTABLE OF CONTENTS
1 Introduction 1
2 An Analytical Poroelastic Model of Convection Enhanced Drug
Delivery 6
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2 Theoretical Background . . . . . . . . . . . . . . . . . . . . . . . . 9
2.2.1 Poroelastic Model of Fluid Transport . . . . . . . . . . . . . 9
2.2.2 Deformation Dependent Hydraulic Permeability . . . . . . . 13
2.2.3 Carman-Kozeny Model . . . . . . . . . . . . . . . . . . . . . 14
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.3.1 Material Properties . . . . . . . . . . . . . . . . . . . . . . . 16
2.3.2 Device Size . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.3.3 Deformation Dependent Hydraulic Permeability and Gel Pore
Size . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3 A Computational Fluid Dynamics Model of the Convection En-
hanced Drug Delivery 30
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2.1 Computational Fluid Dynamics Model . . . . . . . . . . . . 33
3.2.2 In vivo infusion into the hippocampus . . . . . . . . . . . . 36
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.5 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4 Fabrication and Characterization of Microﬂuidic Probes for Con-
vection Enhanced Drug Delivery 43
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4.2 Methods and Materials . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.2.1 Fabrication of microﬂuidic probes . . . . . . . . . . . . . . . 45
4.2.2 Experimental Set-Up . . . . . . . . . . . . . . . . . . . . . . 48
4.2.3 Agarose Brain Phantoms . . . . . . . . . . . . . . . . . . . . 48
4.2.4 Animal Studies . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.2.5 Image Analysis . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.2.6 Model of Molecular Transport . . . . . . . . . . . . . . . . . 52
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.3.1 Device characterization . . . . . . . . . . . . . . . . . . . . . 53
4.3.2 Distributions of infused compounds and backﬂow . . . . . . 54
4.3.3 The eﬀect of diﬀusion on penetration distance . . . . . . . . 60
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
vi4.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5 Multipole Flows for Convection Enhanced Drug Delivery 67
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
5.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.2.1 Calculation of solutions to Laplace’s equation . . . . . . . . 69
5.2.2 Tracer transport and elimination . . . . . . . . . . . . . . . 71
5.2.3 Fabrication of microﬂuidic probes . . . . . . . . . . . . . . . 75
5.2.4 Stratiﬁed brain phantoms and multipole protocols . . . . . . 75
5.2.5 In vivo characterization of line-sinks . . . . . . . . . . . . . 77
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
5.3.1 5-spot ﬂows in homogeneous porous media . . . . . . . . . . 78
5.3.2 Tracer transport in a 5-spot conﬁguration . . . . . . . . . . 79
5.3.3 Tracer transport in a stratiﬁed porous medium . . . . . . . . 86
5.3.4 Characterization of multipole ﬂows in brain phantoms . . . . 86
5.3.5 Characterization of line-sinks in brain phantoms and in vivo 89
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
6 Enhanced Nanoparticle Penetration in the Brain by Remodeling
of the Extracellular Matrix using a Dual Channel Microﬂuidic
Probe 93
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
6.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 97
6.2.1 Microﬂuidic probe fabrication . . . . . . . . . . . . . . . . . 97
6.2.2 Preparation of nanoparticles . . . . . . . . . . . . . . . . . . 98
6.2.3 Animal Experiments . . . . . . . . . . . . . . . . . . . . . . 100
6.2.4 Tissue Analysis . . . . . . . . . . . . . . . . . . . . . . . . . 101
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
6.3.1 Nanoparticles are entrained in perivascular spaces . . . . . . 102
6.3.2 Enzymatic degradation of the extracellular matrix . . . . . . 103
6.3.3 Hydraulic remodeling of the extracellular matrix . . . . . . . 105
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
A Appendix A: Detailed Fabrication Process for Microﬂuidic Probes110
References 117
viiLIST OF TABLES
2.1 Parameters for base case calculations . . . . . . . . . . . . . . . . . 16
4.1 Analysis for the variance of volume of dye in the gray matter be-
tween low (35 kPa), medium (70 kPa), and high (140 kPa) injector
pressures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2 Analysis for the variance of the aspect ratio at 0 mm from bregma
between low (35 kPa), medium (70 kPa), and high (140 kPa) injec-
tor pressures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
6.1 Size and zeta potential of polystyrene nanoparticle before and after
incubation in 1% BSA . . . . . . . . . . . . . . . . . . . . . . . . . 98
viiiLIST OF FIGURES
2.1 The solid matrix displacement, ur, as function of the aggregate
modulus, Ha, which is the sum of the Lam´ e constants (2µ + λ) . . 17
2.2 The fractional change in porosity as a function of the aggregate
modulus, Ha, which is the sum of the Lam´ e constants (2µ + λ) . . 18
2.3 The eﬀect of hydraulic permeability on velocity proﬁle for a con-
stant pressure infusion. Permeability represent approximate val-
ues for white matter (50,000 nm2), gray matter (5000 nm2), and
glioblastoma tumors (500 nm2) . . . . . . . . . . . . . . . . . . . . 19
2.4 The fractional change in porosity as a function of the radius of the
infusion device. The radii represent a 32 gauge needle (120 µm) to
a microﬂuidic channel (10 µm). . . . . . . . . . . . . . . . . . . . . 21
2.5 The relative change in permeability as a function of dilation as
given by eq. 2.32 for diﬀerent gel porosities. . . . . . . . . . . . . . 22
2.6 The gel pore radius given by the Carman-Kozeny relationship (eq.
2.33) as function of dilation for diﬀerent permeabilities . . . . . . . 23
3.1 Two-dimensional coronal slice at -2.85 mm from bregma was con-
verted into a hybrid grid of structured and unstructured elements. 35
3.2 Transient evolution of the concentration proﬁle of an infused drug at
time=0, 6, 12, 18, and 24 min. The color represents the normalized
concentration (c/co) which ranges from 0 (blue) to 1 (red). . . . . . 37
3.3 The eﬀect of the ratio of white matter to gray matter permeability
on drug distribution for values of κw/κg of 5.9 (left), 200 (middle),
1000 (right) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.4 The distribution of 3 kDa dextran (middle) infused into the hip-
pocampus (right) of the rat brain compared to a CFD model with
the same infusion conditions (right). . . . . . . . . . . . . . . . . . 40
4.1 Summary of fabrication process; a) Deposition and patterning of
silicon dioxide etch mask, b) DRIE of backside silicon, c) Deposition
of silicon dioxide etch stop, d) Patterning of photosensitive poly-
imide adhesion layer, e) Patterning of sacriﬁcial photoresist layer,
f) Deposition parylene structural layer , g) Evaporation and pat-
terning of aluminum etch mask, h) Patterning of photoresist etch
mask, i) Patterning of parylene by oxygen plasma, j) DRIE of front
side silicon, k) Deﬁnition of channel inlet and outlet in parylene
by oxygen plasma, l) Dissolution of silicon oxide and aluminum in
buﬀered oxide etch and release of sacriﬁcial photoresist in acetone. 46
4.2 Electron micrographs of microﬂuidic probe. (a) Parylene microﬂu-
idic channel with dimension of 50X10 µm. (b) Pointed tip of in-
sertable portion of probe. (c) Entire probe with protrusion for
ﬂuidic connection (1), base for handling (2) and tissue penetrating
insert (3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
ix4.3 The apparent hydraulic conductivity was calculated using Darcy’s
Law in radial coordinates, where Po = (Q(a)/4πa)κ, for injection
into 0.6% agarose () or brain (). The x-axis is the pressure
at the tip of the device. The injector pressure upstream from the
device was 7-210 kPa. The ﬂow rate was estimated by measuring
the time it took for 1 µL of volume to be expelled through the device
into the gel or tissue. Each symbol represents one infusion. There
were 5-20 measurements taken for each infusion depending on the
infused volume and the error bars represent one standard deviation
from these measurements. Best ﬁts of eq. (2.19) to experimental
data are shown by dashed lines. . . . . . . . . . . . . . . . . . . . . 56
4.4 (a) The microﬂuidic probe with attached ﬂuid reservoir was inserted
3 mm laterally from bregma to a depth of 5 mm into the caudate
nucleus (Top). (b)-(d)An overlay of the processed data on a cartoon
of the insertion site illustrates the pressure dependence of the dye
distribution at injection pressure of 35, 70, and 140 kPa. . . . . . . 57
4.5 Distribution of Evans blue labeled albumin in the caudate of rats
at infusion pressures of (a) 35 kPa, (b) 70 kPa, and (c) 140 kPa.
Each coronal slice is labeled by its position with respect to bregma
(β) in millimeters. The infusion site is at 0.0 mm from bregma. . . 58
4.6 Volume distributed:volume infused of Evans Blue () and albu-
min () into 0.6% agarose at an infusion pressure of 5 kPa and a
comparison to model predictions (–). Each data point represents
a separate infusion. The model accurately predicts the time de-
pendent Vd :Vi observed with infusion of Evans Blue (R2=0.70)
compared to the relatively time insensitive results obtained during
infusion of albumin (R2=0.83). . . . . . . . . . . . . . . . . . . . . 62
5.1 The radially dependent Peclet number as a function of diﬀusivity
for small molecules (10−10), globular proteins (10−11), and linear
macromolecules (10−12) in brain tissue. . . . . . . . . . . . . . . . . 72
5.2 Line sink microﬂuidic probe with 10 µm holes spaced 100 µm apart. 76
5.3 5-spot pressure proﬁle for an infusion pressure of 30 kPa and with-
drawal pressure of 7.5 kPa at sinks a radial distance of 5 mm from
the source. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.4 Tracer transport along 5-spot streamlines for an infusion pressure
of 30 kPa and withdrawal pressure of 7.5 kPa. Upper: The local
Peclet number is greater than one within the solid lines for diﬀusion
coeﬃcients of 10−12 m2/sec (yellow), 10−11 m2/sec (green), and
10−10 m2/sec (red). Lower: Tracer particle position at their half-
life for ﬁrst order elimination constants of 10−5 1/sec (yellow), 10−4
1/sec (green), 10−3 1/sec (red) . . . . . . . . . . . . . . . . . . . . 82
x5.5 Tracer transport along 5-spot streamlines for an infusion pressure
of 30 kPa and withdrawal pressure of 3.8 kPa. Upper: The local
Peclet number is greater than one within the solid lines for diﬀusion
coeﬃcients of 10−12 m2/sec (yellow), 10−11 m2/sec (green), and
10−10 m2/sec (red). Lower: Tracer particle position at their half-
life for ﬁrst order elimination constants of 10−5 1/sec (yellow), 10−4
1/sec (green), 10−3 1/sec (red) . . . . . . . . . . . . . . . . . . . . 83
5.6 The steady-state penetration distance as a function of the ﬁrst-
order elimination constant according to eq. 5.15 for diﬀerent ﬂow
rates at porosity of 0.2. . . . . . . . . . . . . . . . . . . . . . . . . 85
5.7 Streamlines for a stratiﬁed porous medium where the lower half of
the domain has a permeability 100 times greater than the upper
half. Upper: Streamlines for a single source a strength of 30 kPa.
Lower: Streamlines for a dipole ﬂow between a source with strength
of 30 kPa and a sink with strength -0.3 kPa. . . . . . . . . . . . . . 87
5.8 Measuring the permeability of a layered agarose structure using a
ﬁve-channel, three shank microﬂuidic probe. The numbered circles
in the picture of the device correspond to the labels on x-axis of
the graph. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
6.1 Upper: The two channels run parallel to each other along the shank
and have outlets at 0.5 mm from the tip. Lower: Each channel has
its own protrusion for connection to small bore polyimide tubing.
The device is fastened to a custom holder using a screw and washer. 99
6.2 Five microliter infusion of BSA (left), 20 nm polystyrene particles
(middle), and 100 nm polystyrene particles (left) into the caudate
of rats. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
6.3 Upper: The distribution of a 5 µL infusion of 20 nm polystyrene
particles without any pretreatment (left), co-infused with hyper-
osmolar concentration of mannitol (center), and after a 24 hour
digestion of the ECM by hyaluronidase (right). Lower: Volume
of distribution in gray matter for diﬀerent treatments. Error bars
represent one standard deviation for n=3. . . . . . . . . . . . . . . 104
6.4 Volume of distribution of a 5 µL infusion 20 nm and 100 nm parti-
cles in gray matter after 30 minute digestion with either hyaluronidase
or chondroitinase. Error bars represent one standard deviation for
n=3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
6.5 Five microliter infusion of 20 nm polystyrene particles immediately
following a pre-infusion of PBS (left) or mannitol (right). The dis-
tribution of nanoparticles for both treatments was highly localized
around the medial cerebral artery (inside red circle). . . . . . . . . 106
xiCHAPTER 1
INTRODUCTION
Numerous localized drug delivery strategies have been developed to circumvent
the blood-brain barrier. For example, the insertion of polymeric implants that
release drugs slowly into the surrounding tissue has been successful in treating
tissues locally [1]. These implants also can be eﬀective in treating intracranial
tumors with local chemotherapy because high drug doses can be delivered to the
tissue surrounding the implant [2]. However, the distance that a drug penetrates
into the tissue after release depends on the relative rates of drug transport and
drug elimination [3]. When diﬀusion is the dominant transport mechanism, the
concentration of the drug decays exponentially with distance from the implant. In
many instances, only the tissue within a few millimeters of the implant is exposed
to a therapeutically useful drug concentration. In this case, treatment could be
enhanced by alternative delivery methods that increase the penetration distance of
the drug into tissue and eliminate the rapid decay in concentration with distance
that is characteristic of diﬀusion mediated transport.
Convection-enhanced drug delivery (CED) uses direct infusion of a drug-con-
taining liquid into tissue so that transport is dominated by convection. By increas-
ing the rate of infusion, the convection rate can be made large compared with the
elimination rate in a region of tissue about the infusion point. Thus, CED has the
potential of increasing the drug penetration distance and mitigating the decay in
concentration with distance from the release point. In addition, CED may over-
come limitations of traditional treatments for brain tumors caused by the large
tumor size and the diﬃculty of delivering therapeutics into their dense tissue.
Convection-enhanced drug delivery has been tested extensively in animals and
12
humans. Small molecules [4, 5, 6], proteins [7, 8, 9], growth factors [10, 11], and nu-
cleotides [12, 13] have been infused into animal models for therapeutic and imaging
purposes. Chemotherapy agents [14, 15], viral vectors [16], and proteins [17, 18]
have been infused into humans in clinical trials. Initial studies were conﬁned to
infusion in the homogenous, gray matter bodies of the brain [7, 12]. Other studies
have concentrated on the globus pallidus internus [5], peripheral nerves [19], tumors
[11, 14], and the brainstem [20, 9, 21]. The results of these studies indicate that
convection can be used to distribute molecules, regardless of their size, through-
out most regions of the brain. However, was diﬃcult to control the distribution
of infused molecules when characteristics of the tissue vary within the treatment
region, such as in heterogenous tumors [22] and near white matter tracts in the
brain [23]. Clinical trials for treating brain tumors have reported similar problems
in tracking and predicting the distribution of infused chemotherapy agents [24].
The aim of this thesis was to combine models of transport in porous media
with microfabricated devices to develop novel methods for delivering and control-
ling the distribution of infused drugs. Analytical and computational models were
developed to identify the role of infusion conditions and material properties on
transport. In Chapter 2, a poroelastic model was developed that considers the
simplest case of infusion into a homogeneous, isotropic media subject to small de-
formation. From the poroelastic model we can calculate the extent and magnitude
of dilation in tissue surrounding the infusion site. Most models of CED assume
that dilation is negligible or that dilation does not aﬀect porosity. However, we
show that the deformation from dilation can signiﬁcantly change the eﬀective pore
size of the extracellular matrix. At suﬃciently high infusion rates, the pore size of
the ECM can increase by as much as two to three times its undeformed value of ap-3
proximately 50 nm. This result has important consequences when considering the
transport of larger drug delivery vehicles such as viral vectors and nanoparticles.
In Chapter 3, a computation ﬂuid dynamics (CFD) model of the rat brain was
developed to account for a physiologically relevant geometry with heterogeneous
features. This model was used to explore how diﬀerences in permeability between
two layers, gray and white matter, perturb ﬂuid ﬂow. Sensitivity analysis suggested
that beyond a critical ratio between the permeabilities of the two layers there exists
no further perturbation. In essence the higher permeability layer becomes a ﬂuid
sink. The CFD model was used as a prediction tool given estimates of the physical
properties of targeted tissue region. We were able to predict the distribution of an
infused tracer molecule by assuming the critical permeability ratio between features
of the rat hippocampus. Coupled with advanced imaging techniques to determine
physical properties, computational models of the human brain and tumors could
aid clinicians in the placement of catheters for CED protocols.
Chapter 4 describes the fabrication and characterization of microﬂuidic probes
for CED protocols. The rationale behind microfabricated devices was two-fold.
First, empirical evidence during CED suggested that a smaller catheter attenuates
reﬂux between the catheter and the tissue which leads to better drug distribu-
tion at higher infusion rates. Second, a microfabricated device provides for more
ﬂexibility in terms of geometry and delivery strategies, with the capability of mul-
tiple channels delivering multiple solutions. Microﬂuidic channels were formed on
silicon substrates by employing a sacriﬁcial photoresist layer encased in a pary-
lene structural layer. Flow in the microchannels was characterized by applying
constant upstream pressures from 35 to 310 kPa, which resulted in ﬂow rates of
0.5-4.5 µL/min. The devices were used to infuse Evans Blue and albumin in hy-4
drogel brain phantoms. The results of these infusions were compared to a simple
convection-diﬀusion model for infusions into porous media. In vivo infusions of
albumin were performed in the gray matter of rats at upstream pressures of 35,
70, and 140 kPa. The microfabricated probes show reduced evidence of backﬂow
along the device-tissue interface when compared with conventional needles used
for CED.
In the ﬁnal two chapters we use the fabrication process developed in Chapter 4
to make devices for more advanced infusion strategies. Chapter 5 considers the use
of multipole ﬂow for directing infused ﬂuids in porous mediums. Multipole ﬂow
refers to manipulating ﬂow ﬁelds using a conﬁguration of multiple ﬂuid sources and
sinks. This method is commonly used to extract oil and water from subsurface
reservoirs. Using potential ﬂow theory we found that multipole ﬂow was feasible in
the brain within the material and infusion constraints identiﬁed in our theoretical
models and in vivo infusions. Microﬂuidic devices with multiple channels were
fabricated for implementing multipole ﬂow in the brain. These devices were capable
of mapping the permeability of heterogeneous hydrogels and withdrawing ﬂuid
from hydrogels at high ﬂow rates (∼1µL/min). However, the withdrawal of ﬂuid
from brain tissue under negative pressure was not possible from either point sinks
or line sinks.
Finally, chapter 6 considers the challenge of infusing nanoparticles in the brain.
Nanoparticles, including liposomes, viral vectors, and polymeric drug carriers, are
part of promising therapies for a number of brain diseases. But, the large size of
nanoparticles excludes them from passing the blood-brain barrier and also hinders
their transport through the extracellular matrix. We developed a two-channel
microﬂuidic probe for delivering hydraulic and enzymatic treatments to the brain5
prior to nanoparticle infusion to enhance penetration. Monodisperse polystyrene
particles with diﬀerent diameters were used a model system to determine the role of
size on distribution. Two hydraulic treatments were considered to induce dilation
of the extracellular matrix (ECM): 1) An isotonic saline solution was infused at
a high ﬂow rate prior to nanoparticle infusion. 2) A hyperosmolar solution of
mannitol was co-infused with nanoparticles or pre-infused to drive ﬂuid out of
capillaries and cells and into the ECM. The ECM was enzymatically degraded by
pretreating the targeted area with the enzymes hyaluronidase and chondroitinase
for 30 minutes and 24 hours prior to nanoparticle infusion. Co-infusion of mannitol
and 24 hour enzymatic digestion of the ECM with hyaluronidase both increased
nanoparticle penetration two-fold. The ability to deliver multiple solutions to
a single infusion site is one example of the advanced strategies possible with of
microfabricated devices.CHAPTER 2
AN ANALYTICAL POROELASTIC MODEL OF CONVECTION
ENHANCED DRUG DELIVERY
2.1 Introduction
In order to develop devices and protocols for convection enhanced drug delivery
(CED) it is critical to understand the dynamics of pressure driven ﬂows in the
brain and the transport of infused drugs and drug delivery vehicles. This is a
complex problem due to the variety of anatomical features in the brain and varying
physical properties that change within the targeted tissue region. For instance,
white matter is anisotropic and has a much higher hydraulic permeability than
gray matter. White matter tracts are rarely more than a few centimeters from
gray matter in the human brain. In tumors, necrotic zones and leaky blood vessels
can entrain infused drug solutions. More subtle features like the perivascular space
and delineations within gray matter can also perturb ﬂow ﬁelds. Understanding
the fate of infused therapeutics is equally daunting. Infused molecules have steric,
hydrodynamics, and electrostatic interaction with the extracellular matrix and cell
surfaces, in addition to being subject to a variety of elimination mechanisms. To
account for all of these features would require a sophisticated and computationally
expensive model.
In lieu of a comprehensive computational model, analytical models with various
simplifying assumptions have been developed to capture the most salient features
of pressure driven ﬂows in the brain. Most of these models assume a homoge-
neous, isotropic porous media. There are two types of models; one that treats
tissue as a rigid porous media [25, 26] and another which attempts to capture its
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mechanical properties using poroelastic and poroviscoelastic constitutive assump-
tions [27, 28, 29]. These models can be characterized by how they deﬁne the volume
ﬂuid fraction, or porosity, φ. The rigid pore model assumes a constant porosity,
the poroelastic model treats the porosity as a function of dilation, φ = f(e), and
the poroviscoelastic model also incorporates transient eﬀects, φ = f(e,t), such as
the relaxation of the polymer chains in the extracellular matrix.
The rigid pore assumption holds when deformation of tissue is negligible. One
instance of negligible deformation is the tissue adjacent to the vasculature. Baxter
and Jain used a rigid pore model to describe the transvascular and extravascular
transport of ﬂuid and macromolecules in tumors [25]. Their model accurately
predicts the pressure gradient and drug distribution commonly reported in brain
tumors. Morrison and colleagues have used this model to predict the penetration
of macromolecules by convection enhanced delivery in the brain and spinal cord
[26, 5, 30, 31]. Even though there is most likely deformation at the infusion point,
Morrison argues that the aﬀect is local and does not signiﬁcantly alter transport.
Poroelastic models account for the eﬀect of infusion induced swelling on ﬂuid
ﬂow and describes the normal and shear stresses imposed on the porous media.
The most widely accepted poroelastic model of tissue is based on Biot’s theory
of consolidation [32] which treats a porous media as two phases, solid and liquid.
The poroelastic model accurately predicts the behavior of soft tissues under both
compression and tension [33, 34]. Studies by Basser [27] and Netti and colleagues
[28, 29] were the ﬁrst to combine the poroelastic constitutive assumption with
ﬂuid and macromolecular transport in the brain. Both groups determined that
swelling during infusion into the brain was signiﬁcant and would ultimately eﬀect
drug transport. A simpler model, although still based on poroelastic theory, has8
been used to predict concentration and pressure proﬁles in agarose gels in good
agreement with experimental data [35].
The poroelastic model describes the dilation of infused tissue which can impact
transport of infused macromolecules, viruses, and nanoparticles. As the tissue di-
lates, the water content increases, and consequently the space between the ﬁbers
of the extracellular matrix increases. The hydraulic permeability, which is an indi-
rect measurement of the spacing between ﬁbers, also increases. The deformation
dependence of hydraulic permeability has been demonstrated in hydrogels [36, 37],
cartilage [38], brain tissue [39], and tumors [40]. Theoretical expressions based on
hydrodynamic arguments have been derived which express the hydraulic perme-
ability solely as a function of the water content [41, 42, 43]. Conﬁned compression
experiments in gels and cartilage have yielded empirical expression of permeability
for gels and cartilage [38, 36, 44, 37]. The theoretical expressions tend to under-
estimate permeability at high porosities (φ > 0.95) due to heterogeneities of gels
near their critical gel concentration [45]. Gu and colleagues developed a power law
expression for the deformation dependent permeability of gels and cartilage that
holds even at high porosity [37].
Here we adapt Biot’s consolidation model for a constant pressure infusion into
a homogeneous poroelastic media. Sensitivity analysis on physical properties illus-
trate the need to adjust infusion conditions for diﬀerent materials. The dilation
predicted from the consolidation model was used to estimate changes in hydraulic
permeability using an empirical model. The changes in hydraulic permeability are
used to calculate a pore size from the Carman-Kozeny equation for random ﬁbrous
media. The implications on device design, infusion conditions, and transport are
discussed.9
2.2 Theoretical Background
2.2.1 Poroelastic Model of Fluid Transport
The poroelastic model for divergent ﬂow from a single source consists of two conser-
vation equations, mass and momentum, and two constitutive relationships, Darcy’s
Law and linear elasticity. The pressure, velocity, dilation, and deformation tensor
can be calculated from these equations. The major assumptions of the model are:
1) The poroelastic medium is a ﬂuid saturated, elastic network with communicat-
ing ﬂuid ﬁlled pores. 2) The tissue is compressible, homogeneous, and isotropic.
3) The geometry of the system is axisymmetric.
Assuming the density of the liquid and ﬂuid phase are the same, then the
conservation of mass for each phase is
∂φ
∂t
= −∇ · φv (2.1)
∂(1 − φ)
∂t
= −∇ ·

(1 − φ)
∂u
∂t

(2.2)
where φ is the ﬂuid volume fraction or porosity, v is the ﬂuid velocity vector, and
u is the solid matrix displacement. The conservation of momentum for the solid
matrix is
∇ · τ = 0 (2.3)
where τ is the eﬀective stress tensor and under the assumption of linear elasticity
and ignoring body forces is expressed as
τ = 2µε + λeI − PI (2.4)
where µ is the shear modulus, ε is the deformation tensor, λ is the second Lam´ e
constant, e is the dilation, I is the identity matrix, and P is hydrostatic pressure.10
For an axisymmetric geometry the deformation tensor is
ε =

  


∂ur
∂r 0 0
0 ur
r 0
0 0 ur
r

  


(2.5)
The network dilation, e, is the divergence of the solid displacement vector
e = Tr(ε) =
∂ur
∂r
+ 2
ur
r
= ∇ · u (2.6)
Substituting the linear elasticity relationship, equation 2.4, into the momentum
balance gives
∇ · τ = 2µ∇ · ε + λ∇eI − ∇ · PI = 0 (2.7)
Equation 2.7 can be expressed solely in terms of the dilation using equation 2.6
∇ · τ = 2µ∇e + λ∇e − ∇P = 0 (2.8)
Taking the divergence of equation 2.8
(2µ + λ)∇
2e = ∇
2P (2.9)
Adding the ﬂuid (equation 2.1) and solid (equation 2.2) parts of the conservation
of mass and taking the divergence yields
(1 − φ)
∂e
∂t
+ φ∇ · v (2.10)
A generalized form of Darcy’s Law is needed to account for the relative ﬂuid
velocity with respect to the matrix displacement
φ

v +
∂u
∂t

= −κ∇P (2.11)
where κ is the hydraulic conductivity. Taking the divergence of equation 2.11 gives
φ

∇ · v +
∂e
∂t

= −κ∇
2P (2.12)11
Equations 2.9, 2.10, and 2.11 can be combined to give the consolidation equation
∂e
∂t
= −κ(2µ + λ)∇
2e = −c∇
2e (2.13)
where c is called the coeﬃcient of consolidation. The consolidation equation takes
the form of the transient diﬀusion equation with the coeﬃcient of consolidation as
a pseudo-diﬀusion coeﬃcient.
Assuming steady state and purely radial ﬂow, eq. (2.1) becomes
1
r2
∂
∂r
(r
2vr) = 0 (2.14)
which is integrated to obtain
vr =
A
r2 (2.15)
Substituting eq. (2.15) into eq. (2.11) and integrating yields
P(r) =
φ
κ
A
r
+ B (2.16)
The integration constants A and B are found by assuming that the pressure de-
creases to zero at inﬁnity and that P(a)=Po, where Po is the pressure inside a
ﬂuid-ﬁlled cavity of radius a about the tip of the microﬂuidic channel. Evaluating
the constants gives the following pressure and velocity proﬁles
P(r)
Po
=
a
r
(2.17)
vr(r) =
Poκa
φr2 (2.18)
The volumetric ﬂow rate at the channel tip is
Q(a) = φvr(a)4πa
2 = 4πaκPo (2.19)12
Eq. (2.19) suggests that a plot of Q(a)/4πa as a function of Po should give a
straight line with a slope that is an apparent conductivity of the medium. This
relationship is exploited in Chapter 1 to measure the hydraulic permeability of
agarose and gray matter in the rat brain. One should note that equations 2.17 and
2.18 are identical for the rigid pore model.
The advantage of the poroelastic model over the rigid pore model is that it can
account for changes in porosity as a function of dilation and calculate the resul-
tant stress ﬁelds. The solid matrix displacement, ur, can be found by combining
equations 2.6 and 2.9 and solving the heterogeneous diﬀerential equation with the
boundary conditions of no contact stress at the cavity interface (r = a) and far
from the cavity (r = ∞):
ur =
Poa
2µ + λ

1 +
λ
2µ
a2
r2

(2.20)
Calculating the steady state dilation using equation 2.6 yields
e =
Poa
(2µ + λ)r
(2.21)
For small deformation, the dilation can be reexpressed in terms of the change
in volume due to an increase in water content:
e =
δVt
V 0
t
=
Vt − V 0
t
V 0
t
(2.22)
where V 0
t is the unstressed total volume of the system and Vt is the deformed
volume. Under the assumption that only the liquid fraction of the volume changes,
then V 0
f = φ0V 0
t , where φ0 and V 0
f is the unstressed liquid fraction and liquid
volume respectively. The changed in volume can be rewritten in terms of the
liquid fraction
Vt − V
0
t = Vf − V
0
f = Vtφ − V
0
t φ0 (2.23)13
Equations 2.22 and 2.23 are combined to give the stressed pore volume
φ =
e + φ0
1 + e
(2.24)
Equation 2.24 can be evaluated with equation 2.21 to determine the eﬀect of infu-
sion conditions and material properties on porosity.
We can now apply the dilation and solid matrix displacement to ﬁnd the solid
stress and strain ﬁelds (eq. 2.7) for a radial source ﬂow in a poroelastic medium.
There are two stresses within the solid phase for infusion into a spherically symmet-
ric geometry. The radial stress, which is always negative, compresses the adjacent
tissue in the radial direction. The circumferential stress, which is always positive,
pulls or creates tension in theta and phi directions. For a constant pressure infusion
the radial stress is
τrr = 2µ
∂ur
∂r
+ λe(r) − P(r) (2.25)
τrr = −Poa

a2λ/µ + 2r2
(2 + λ/µ)r3

(2.26)
and the circumferential stress is
τθθ = τφφ = 2µ
ur
r
+ λe(r) − P(r) (2.27)
τθθ = τφφ = Poa

a2λ/µ − 2µr2
2(2 + λ/µ)r3

(2.28)
2.2.2 Deformation Dependent Hydraulic Permeability
As derived in the previous section, the water fraction is related the dilation (eq.
2.24). The solid fraction (1 − φ) is comprised of the space occupied by both cells
and the ﬁbers of the extracellular matrix (ECM). However, the cell membrane is14
relatively impermeable compared to ﬂow through the ECM and the resistance to
ﬂow is almost completely due to viscous eﬀects of ﬂow through the ECM [46].
These two observations suggest that we can assume that dilation is due solely to
deformation of the ECM and we can rewrite eq. 2.24 in terms of the gel porosity,
,
 =
e + 0
1 + e
=
J − 1 + 0
J
(2.29)
where J(= dV/dV0) is the ratio of current volume (dV ) to the undeformed volume
(dV0), and thus the dilation is e = J − 1. Gu and colleagues developed a power
law expression between hydraulic permeability and water content [37]. Their ex-
pression agrees with experimental data for both agarose at concentration between
2-15% [36] and bovine articular cartilage [38]. The empirical expression is
k = α


1 − 
n
(2.30)
where α = 0.00339 nm2, n = 3.236, and k is given in units of nm2. The hydraulic
permeability (κ) is often expressed in term of the Darcy permeability, k = κ/µ,
where µ is the viscosity of the solution.
Subsituting eqn. 4.3 into eq. 4.4 gives the expression for deformation dependent
permeability:
k = α

 + e
1 − 
n
(2.31)
Equation 2.31 can be rewritten in terms of the reference permeability (e=0):
k = k0

 + e

n
(2.32)
2.2.3 Carman-Kozeny Model
It is tempting to use the square root of the hydraulic permeability as an eﬀective
“pore size.” However, a more rigorous theory for ﬁbrous media relates permeability15
to the structure of the matrix is the Carman-Kozenzy equation: [47]
k =
r2
p
G
(2.33)
where rp is the gel pore radius, and G is the Kozeny factor. The Kozeny factor
takes into account the geometry of the ﬁbrous matrix. Theoretical expressions
were developed from hydrodynamic arguments [48] to separate G into parallel
(Gk) and perpendicular (G⊥) components with respect to ﬂow across a cylinder.
For cylinders parallel to the ﬂow:
Gk = 2
3/{(1 − ) · [2ln(1/(1 − )) − 3 + 4 · (1 − ) − (1 − )
2]} (2.34)
For cylinders perpendicular to the ﬂow:
G⊥ = 2
3/{(1 − ) · [ln(1/(1 − )) − ((1 − (1 − )
2)/(1 + (1 − )
2))]} (2.35)
For a randomly oriented ﬁbrous matrix the Kozeny factor becomes
G = (2G⊥ + Gk)/3 (2.36)
2.3 Results
Sensitivity analysis on the poroelastic model were performed to demonstrate how
changes in infusion conditions and material properties impact drug delivery. All
the sensitivity analysis presented are based on the values in Table 2.1 and only
the parameter indicated in each graph was changed. The material properties in
Table 2.1 are an average of values for gray matter found in the literature and
the infusion conditions are based on our experiences with in vivo infusions using
microﬂuidic probes [49]. An infusion pressure of 10 kPa translates to a ﬂow rate
of approximately 2 µL/min in gray matter.16
Table 2.1: Parameters for base case calculations
Parameter Value Description
PO 10 kPa Infusion pressure
a 50 µm Radius of delivery device
φ 0.2 Tissue porosity
 0.85 ECM porosity
κ 5 X 10−12 m2/Pa s hydraulic permeability
µ 5 kPa Shear modulus
λ 90 kPa 2nd Lam´ e constant
2.3.1 Material Properties
The key material properties in the poroelastic model are the Lam´ e constants, µ
(also called the shear modulus) and λ, and the hydraulic permeability. The sum
of the Lam´ e constants (2µ + λ) is referred to as the aggregate modulus, Ha, and
can be thought of as the stiﬀness of the porous media. For an applied force, in our
case a constant pressure at the device tip, the solid matrix will deform by com-
pressing in the radial direction. The solid matrix displacement, ur, is indirectly
proportional to the aggregate modulus (eq. 2.20). A stiﬀer material (larger aggre-
gate modulus) is less deformable and thus the solid matrix displacement is smaller.
Note that the solid matrix displacement is also a function of the ratio of the Lam´ e
constants. For an incompressible medium like brain tissue and some hydrogels
the ratio (λ/µ) generally has a magnitude of 40-50 [50], but for hydrogels is also
dependent on concentration and cross-linking density. Figures 2.1 and 2.2 shows
the radial dependence of the solid matrix displacement and porosity for aggregate
modulus values for a low weight percentage (<1%) agarose (5 kPa), white matter17
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Figure 2.1: The solid matrix displacement, ur, as function of the aggregate
modulus, Ha, which is the sum of the Lam´ e constants (2µ + λ)
(50 kPa), and gray matter (100 kPa). The eﬀect was moderate for both types of
brain tissue, but for low weight fraction agarose, the displacement is O(100 µm)
and there was up 200% increase in porosity at the device-tissue interface.
The hydraulic permeability measures the resistance to ﬂow under an applied
pressure gradient as deﬁned by Darcy’s law (eq. 2.11). Figure 2.3 demonstrates the
dependence of the radial velocity on hydraulic permeability at an infusion pressure
of 10 kPa. The magnitude of the hydraulic permeability can range over several
orders of magnitude between diﬀerent anatomical features in the brain as well as
between tumor types [51]. Furthermore, the permeability changes the increase
in water content during infusion in a non-linear way. As a result, a doubling in
infusion pressure could lead to much more than a doubling in velocity. The strong
dependence of velocity on permeability underscores the importance of considering18
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Figure 2.3: The eﬀect of hydraulic permeability on velocity proﬁle for a con-
stant pressure infusion. Permeability represent approximate val-
ues for white matter (50,000 nm2), gray matter (5000 nm2), and
glioblastoma tumors (500 nm2)20
material properties when choosing infusion conditions. It is also important to note
that while mechanical properties and permeability were treated as independent
parameters for the purpose of this analysis, they are actually strongly related to
one another. For instance, increasing agarose concentration leads a concomitant
increase in aggregate modulus and hydraulic permeability [37].
2.3.2 Device Size
The radius of the infusion catheter appears in the expressions for pressure, ﬂuid
velocity, matrix displacement, and dilation. As the catheter size decreases the
volume of tissue that is subjected to elevated levels of stress also decreases. This is
illustrated in Figure 2.4 where the swelling becomes more local as the device radius,
a, decreases. The magnitude for stress at the infusion site, r = a, is independent
of catheter size, but decays faster for smaller catheters. If equation 2.19 is used
to estimate hydraulic permeability, then an accurate estimation of the size of the
ﬂuid ﬁlled cavity at the infusion site is important. We have assumed that the size
of the cavity is equivalent to the catheter radius, but displacement of the adjacent
tissue could lead to an increase in the cavity size. The solid network displacement
can be minimized with a small device as predicted by equation 2.20.
2.3.3 Deformation Dependent Hydraulic Permeability and
Gel Pore Size
Figure 2.5 shows the change in the relative permeability (k/ko) for typical dilation
range (0.1-0.5) calculated from the consolidation model for high ﬂow infusion into
brain tissue using an empirical model that was ﬁt to agarose data [37]. The change
in permeability moderately increases with increasing gel porosity, ranging from 3X-21
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Figure 2.5: The relative change in permeability as a function of dilation as
given by eq. 2.32 for diﬀerent gel porosities.
4.5X increase for porosities of 0.70-0.99. The porosity of the ECM of the brain has
not been measured, so we used a range that included cartilage with a high collagen
content (0.85) [46] to low weight percentage agarose (0.99) [36].
An increase in permeability will yield a proportional increase in velocity ac-
cording to Darcy’s law for a given pressure.
Figure 2.6 demonstrates the change in pore radius with dilation for perme-
abilities meant to represent a range including dense tumor tissue, normal brain
tissue, and hydrogels. Since the pore radius goes as the square root of the perme-
ability, increases in pore size are approximately 2X-2.5X. Of interest is the strong
correlation between permeability and pore size (eq. 2.33) which suggests that per-
meability provides size exclusion data for a given porous media. For instance, the23
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Figure 2.6: The gel pore radius given by the Carman-Kozeny relationship
(eq. 2.33) as function of dilation for diﬀerent permeabilities24
transport of nanoparticles with a diameter of ≈100 nm could pass through white
matter, but would be severely hindered in gray matter and some tumor tissues.
2.4 Discussion
Poroelastic theory is a useful tool to explore the interplay between ﬂuid ﬂow and
material mechanics in soft materials . Here, we have applied Biot’s consolidation
model to a constant pressure infusion from a source with a ﬁnite size into a homo-
geneous, isotropic porous media . Sensitivity analysis was performed on material
properties, catheter size, and dilation that are relevant for scenarios encountered
during CED. Several simplifying assumptions were made to allow for closed form
solutions of the governing equations. The water losses to the vascular system were
ignored even though elevated pressure can lead to a increase in transvascular ﬂux
[28]. However, it has been argued that for the high ﬂow rates used for CED, wa-
ter losses are minimal and do not signiﬁcantly alter ﬂuid ﬂuid ﬂow or transport
[29]. An isotropic, homogeneous media misrepresents the brain on the centimeter
scale, but is not an unreasonable assumption at the few millimeters adjacent to
the infusion sight.
The model predicts tissue deformation to be local, extending not beyond a
few millimeters from the infusion site (Figure 2.4). If this is true, then the rigid
pore assumption used by other researchers [26, 5, 30, 31] to describe transport is
probably accurate on the centimeter scale. But this result is highly dependent
on boundary conditions. In our model we have assumed an open system where
pressure approaches zero at a radial distance of inﬁnity. However, the brain is
not an open system, it is encased in a rigid skull and has only a few pathways for
transporting excess ﬂuid out of extracellular spaces. More speciﬁcally, in endoge-25
nous tissue the interstitial ﬂuid generated by the capillaries moves preferentially
in perivascular spaces and axon tracts towards the ventricles and subarchnoid
spaces[52]. It is conceivable that this ﬂuid removal system could be overwhelmed
by the ﬂow rates involved in CED. If we assume a constant ﬂux boundary condi-
tion of 0.1-0.3 µL/min/g brain [52] at a radial distance of 1 cm, then the pressure
remains almost uniform (10 kPa) throughout a 2 cm sphere of porous media with
the material properties of gray matter. Even at ﬂuxes 10-100 times the endoge-
nous ﬂux, the pressure remains within 20% of the infusion pressure. In an actual
brain, the situation is probably somewhere between these two cases and whether
or not deformation should be included in a description of transport depends on
the situation.
The other boundary condition worth examining is no contact stress at the
infusion site. With this boundary condition the adjacent tissue is free to move
away (u 6= 0) from the infusion site because of the infusion induced stress. This
is true for most CED protocols where a catheter is inserted into a targeted region
followed immediately by infusion. This moving boundary is also the cause of reﬂux
of infused solutions along the catheter-tissue interface. This phenomenon, often
called backﬂow, is the cause of many treatment induced complication in CED [24].
Backﬂow leads to poor control over the fate of infused drugs which often end up in
healthy tissue. The degree of backﬂow is a function of the material properties of
the tissue and the infused solution, the ﬂow rate, and the device size [53]. Many of
these problems could be solved by promoting adhesion between the catheter and
tissue. Adhesion between microelectrodes and brain tissue has been promoted by
altering topography [54] and immobilizing proteins on silicon substrates [55, 56].
If such an interface could be engineered for CED the backﬂow problem could be26
reduced. In a derivation not presented here, we changed the boundary condition
at the infusion site to no tissue displacement instead of no contact stress. The
dilation was zero at the infusion site, peaked at 25 µm from the infusion site, and
then followed an similar decay as shown in Figure 2.4. There was essentially no
change in the magnitude or distribution pressure or stress.
In terms of designing devices, the model suggests that smaller is better with
respect to minimizing stress, and hence backﬂow. This result has been empirically
determine in previous studies on CED into the gray matter of rats [57] and theo-
retically here. Stainless steel needles are limited to a radius of 120 µm. Fused silica
and polyimide tubing can be as small as 75 µm in radius, but lacks the rigidity
to penetrate into deep tissue structures. Krauze and colleagues have addressed
the rigidity issue by developing a step-down catheter consisting of fused silica tub-
ing inside of stainless steel needle [58]. Silicon devices have been fabricated with
cross-sections as small at 50 X 50 µm and are still rigid enough to penetrate tissue
[49].
At the infusion point the model predicts no greater than a 5X increase in per-
meability for materials with undeformed permeabilities ranging from 100-10,000
nm2. Zhang and Yuan reported an increase in permeability of four orders of mag-
nitude at an infusion pressure of 15 kPa into an excised tumor [40]. Similarly,
Dillehay found a dramatic decrease in ﬂuid resistance with increasing ﬂow rate
(20-100 µL/min) in xenografted tumors [59]. It has been hypothesized that “water
channels” open up or connect to enable ﬂuid ﬂow through the extracellular spaces
at elevated pressures [60, 40]. However, a permeability of 10−3 nm2, as reported
by Zhang and Yuan, has almost no physical meaning and indicates essentially no
resistance to ﬂow. These results could be explained by some type of mechanical27
failure, perhaps due to the tensile component of the stress tensor, followed by the
opening of a highly permeable fracture.
Another notable result of a deformation dependent permeability the added
complexity it adds to planning CED protocols. In every model of CED, a constant
permeability has been assumed even in models that explicitly account for tissue
elasticity [27, 53]. Scaling relationships have been derived [53] and implemented
[61] based on these models to help researcher scale-up animal models to human
clinical trials. However, by not taking into account changes in permeability, large
errors could be introduced with respect to velocity and pressure proﬁles.
There seems to be contradiction between the reported permeability of the brain
and the reported pore size. Most estimates of the permeability of gray matter are
on the order of 1000-10,000 nm2 [27, 53, 49] which correlated to a pore radius of
approximately 100-300 nm. However, diﬀusion of quantum dots in the neocortex
suggests a pore radius of 20-30 nm [62] which would indicate a permeability on
the order of 100 nm2. Interestingly, 10-100 nm2 is the permeability reported for
hydrogels [36, 45], cartilage [37], and many types of tumors [51]. One possible
explanation for high permeabilities reported for gray matter may be the technique
used to determine permeability in some of these reports [53, 49]. If the permeability
is determined by measuring the ﬂow rate rate at a given pressure at the infusion
point, as suggested by equation 2.19, there is an assumption that the the ﬂuid
ﬁlled cavity radius (a) is known and constant. It has been assumed that the cavity
radius is equivalent to the radius of the catheter. But, as we have determined from
the poroelastic model, the cavity radius will increase with increasing pressure.
This deformation of the cavity could lead to errors when calculating permeability.
A second source of error could be that the high permeability of the perivascular28
space is skewing the measurement. The perivascular space has been implicated as a
preferred pathway for infused liposomes into healthy gray matter of rats [63]. Fluid
reabsorption by blood vessels and lymphatics can also lead to an overestimation
of permeability [22].
If we assume the hydraulic permeability of the ECM is closer to 100 nm2 es-
timates, then the transport of nanoparticles will be severely hindered in gel pores
with radii of 20-30 nm. This conclusion is supported by reports of low penetra-
tion of liposomes [64] and polystyrene nanoparticles [65] with diameters greater
than 100 nm during CED into gray matter. Interestingly, viral vectors such as
adeno-associated viruses (20 nm) and adenovirus (80 nm) have been reported to
penetrate gray matter in rats [65] and monkeys [66]. The dilation of the pores of
the ECM, as predicted from the poroelastic model, may allow particles up to 100
nm in diameter to penetrate during CED protocols.
2.5 Conclusion
The consolidation model is a useful tool for investigating the interplay between
infusion conditions, material properties, and transport for CED protocols. Several
conclusions can be drawn from the sensitivity analysis presented in this study: 1)
Eﬀective CED protocols can only be devised with knowledge of the mechanical
properties and permeability of a targeted tissue. 2) An accurate description of
transport during CED should include tissue dilation. 3) Reduction of device size
should lead to a decrease in backﬂow and minimization of stress on adjacent tis-
sue. 4) Macromolecules with diameters less than 10 nm should be able to penetrate
the ECM with minimal dilation of tissue. 5) Particles and viruses with diameters
10-100 nm could penetrate ECM provided adequate tissue dilation. 6) Particles29
greater than 100 nm in diameter will be severely hindered by the ECM and may
beneﬁt from degradation of ECM components to achieve relevant penetration dis-
tances.CHAPTER 3
A COMPUTATIONAL FLUID DYNAMICS MODEL OF THE
CONVECTION ENHANCED DRUG DELIVERY
3.1 Introduction
Animal tests and early clinical trials of convection enhanced drug delivery for brain
tumors have had mixed results [24]. In certain animal tumor models, the entire
tumor was eliminated using high concentrations of approved chemotherapy drugs
[67]. In other more realistic tumor models, infused drugs tended to accumulate
in necrotic zones and not penetrate into large portions of the tumor [68]. Some
human subjects had no detectable traces of tumor cells after several days of infu-
sions of Taxol [14] and [18], but in many other cases, large portions of tumors were
unaﬀected by the infusions. Furthermore, several complications associated with
the infusion treatement were reported. It seems that the success of CED, as it is
currently applied, is limited to treating patients with relatively homogeneous tu-
mors that are not near highly permeable white matter tracts or ventricles. Clearly
this is an unacceptable result for this promising technique.
As of this writing, clinicians have little rational basis for selecting catheter
placement and infusion parameters even though there are imaging techniques that
can clearly delineate features of tumors. A computational model of ﬂuid ﬂow in
the brain could serve as a predictive tool in conjunction with these imaging tech-
niques to yield more eﬀective CED protocols. The complexity of this problem
should not be understated. Developing a three-dimensional porous media model
of heterogeneous and anisotropic features of the brain and tumors that are recon-
structed from MR images requires accurate estimates of physical properties such
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as hydraulic permeability, diﬀusion coeﬃcient, and porosity as well as substantial
computational power.
There have been a number of two-dimensional models that include some of
these features. Nagashima and colleagues used ﬁnite element methods to solve
ﬂuid ﬂow and mechanical deformation in an anatomically relevant model of brain
edema [69]. Their two-dimensional poroelastic model incorporated bulk ﬂuid ﬂow,
linear elasticity, and ﬂuid exchange between capillaries and the brain extracellular
spaces. White matter was assumed, without explanation, to be 50 times more
permeable than gray matter. Edema was simulated by allowing the hydraulic
conductivity of the blood-brain barrier to increase by 100 times its normal value,
resulting in a local pressure gradient around the lesion. Simulations showed good
agreement with a cold-injury model of edema in terms of changes in interstitial
pressure, increases water content, and brain deformation.
Kalyanasundaram used ﬁnite element methods to describe drug distribution
from polymer implants and bolus injections in the brain [70]. Parameter estimation
from magnetic resonance studies was used in a rigid pore model with diﬀerentiation
between white and gray matter and transport across capillaries. Model predictions
and experimental data conﬁrmed a vast diﬀerence in ﬂuid ﬂow between the white
and gray matter. Permeability in white tissue was reported as three orders of mag-
nitude greater than grey tissue, but with no justiﬁcation given by the authors. In
a similar treatment as Nagashima and colleagues [69], Kalyanasundaram’s model
accounted for the edema induced by the injury sustained during polymer implan-
tation. Peclet numbers as high as 10 were sustained for up to 12 hours at the site
of implantation. They concluded that models that only consider diﬀusive trans-
port from controlled release polymers in the brain will severely underestimate drug32
penetration and clearance.
The only three-dimensional computational models of CED to date are those
developed by Sarntinoranont and colleagues for direction infusion into the spinal
cord [30, 31]. These models took a single two-dimensional image and extended into
three dimensions. A three-dimensional model of the rat spinal cord was developed
to explore the sensitivity of macromolecular transport on porosity and hydraulic
permeability of gray (κg)and white matter (κw). The hydraulic permeability of
the white matter was described by a two dimensional tensor that distinguished
between ﬂow parallel (κwz) and perpendicular (κwx) to axonal ﬁbers. It was found
that ratios of κwz/κwx = 20 and κwx/κg = 100 best ﬁt experimental data for a
porosity of 0.26 [30]. For macromolecular transport the ratio of permeabilities
determined distribution, while the magnitudes had little eﬀect. This spinal cord
model was extended to include degradation and binding terms to characterize
treatment protocols for chronic pain using SP-diphtheria toxin fusion protein [31].
In this study we have developed two-dimensional ﬁnite volume model of the
rat brain for solving the appropriate conservation equations (mass, momentum,
and species). We use this model to explore the eﬀect diﬀerences in hydraulic
permeability between white and gray matter have on ﬂuid ﬂow. The results suggest
that there is no further perturbation of the ﬂow ﬁeld above a critical ratio of κw/κg
of 200. The model was used to predict distribution of 3 kDa dextran into the highly
irregular anatomy of the hippocampus in the rat brain.33
3.2 Methods
3.2.1 Computational Fluid Dynamics Model
Transport through porous media is governed by the conservation of mass, momen-
tum, and species. The pore dimension is assumed to be much smaller than the
overall volume of the system. The volume averaged equation for mass and momen-
tum in a rigid pore model used in the CFD-ACE+ software (Computation Fluid
Dynamics Research Corporation, Huntsville, AL) are deﬁned as [71]
∂
∂t
(φρ) + ∇ · (φρv) = 0 (3.1)
∂
∂t
(φρv) + ∇ · (φρvv) = −φ∇P + ∇ · (φτ) + φB −
φ2µ
κ
v −
φ3CFρ
√
κ
|v|v (3.2)
where ρ is the ﬂuid density, P is the pressure, µ is the viscosity of the ﬂuid, CF
is a quadratic drag factor, τ is the shear stress tensor, B is the body force vector,
v is the ﬂuid velocity, φ is the porosity, κ is the permeability. The last two terms
of eq. 3.2 represent an additional drag force imposed by the pore walls on the
ﬂuid within the pores, and usually results in a signiﬁcant pressure drop across the
porous solid.
The mass conservation for each species is deﬁned as:
∂
∂t
(φρYi) + ∇ · (φρvYi) = ∇ · Ji + ωi (3.3)
where Yi are the mass-fractions of the i-th species, and ωi are the production rates
used to deﬁne chemical reactions. The species ﬂux, Ji, represents Fickian diﬀusion
and contains correction terms necessary to satisfy the Stefan-Maxwell equations
for multi-component species systems. In the absence of information for a full34
multicomponent diﬀusion model, an eﬀective diﬀusion coeﬃcient through porous
media is deﬁned
Di,eff =
3φ − 1
2φ
Di (3.4)
where Di,eff is the eﬀective mass diﬀusion and Di is the diﬀusion coeﬃcient in
water.
The partial diﬀerential equations 3.1, 3.2, 3.3 are solved by discretizing them
on a computational grid, forming a set of algebraic equations, and solving the set
of algebraic equations. In CFD-ACE+, the ﬁnite-volume approach is adopted due
to its capacity of conserving solution quantities. The solution domain is divided
into a number of cells known as control volumes. The governing equations are
numerically integrated over each of these computational cells or control volumes.
A detailed description of the numerical methods can be found in Volume 2 of
the CFD-ACE+ user manual [72]. For the simulations presented here, a ﬁrst-order
upwind scheme was used to discretize the convection terms and algebraic equations
were solved with an algebraic multi-grid (AMG) solver.
A map of the rat brain [73] that delineates gray and white matter regions as
well as the ventricular system was used to build a hybrid grid for solving the ﬂuid
ﬂow equations. Fig. 3.1 shows a coronal slice at -2.85 mm from bregma with the
illustration [73] and corresponding grid. A catheter with a diameter of 250 µm
was placed 2 mm deep into the brain; in this case the tip of the catheter is in
gray matter. The grid is a hybrid of structured and unstructured grids consisting
of 85,000 cells and 48,000 nodes. The structured grid, which is more stable and
converges quickly, was constructed around the infusion site, the tissue adjacent to
the catheter, and at interfaces between white and gray matter. An unstructured
grid was generated using CFD-GEOM algorithms to ﬁll in the remaining areas.35
1 mm
Figure 3.1: Two-dimensional coronal slice at -2.85 mm from bregma was
converted into a hybrid grid of structured and unstructured ele-
ments.
The infusion rate is set to 0.5 µL/min and held constant for the entire infusion.
To show eﬀects of the diﬀerence between white and gray matter, we treat the
hydraulic conductivities of gray and white matter, κg and κw, respectively, as
simulation parameters. Because the simulations considered only a slice of the
brain, the gray and white matter were assumed to be isotropic within the slice.
Subdural and ventricular pressures were set to zero and the pressure at the catheter
outlet was chosen to give the appropriate infusion rate. Drag force was neglected
owing to the small size of the solute. The porosity for both white and gray matter
was 0.2 and the gray matter permeability was 1000 nm2. A diﬀusion coeﬃcient of
8 X 10−7 cm2/s was used from measurements of 3 kDa dextran in cortical slices
[74].36
3.2.2 In vivo infusion into the hippocampus
Adult male Sprague-Dawley rats (180-200 g) were used to characterize the perfor-
mance of devices in vivo. Rats were anesthetized with ketamine (100 mg/kg) and
xylyzine (10 mg/kg) solution via intraperitoneal injection. An incision was made
and a 1 mm diameter hole was drilled in the skull 2.85 mm laterally from bregma
(0 mm AP). Polyimide tubing (OD=250 µm) was inserted into the brain with a
micromanipulator. A solution 0.1% 3 kDa dextran-Texas red was infused at 0.5
µL/min into the hippocampus. The ﬂow rate was maintained with a programmable
syringe pump (PHD2000, Harvard Apparatus). After 2 µL of the solution was in-
fused, the tubing was promptly removed. The animals were immediately perfusion
ﬁxed using a 4% paraformaldehyde solution. Brains were removed, blocked, and
cut into 100µm slices using a vibratome. Tissue slices were mounted in chambers
made on slides containing mounting media (95% glycerol, 5% MBMS, n-propyl-
gallate) and imaged using a scanning confocal system mounted on an inverted
microscope. All procedures were done in accordance with the regulations of the
Yale University Institutional Animal Care and Use Committee.
3.3 Results
Typical simulation results are shown in Fig. 3.2, which illustrates the predicted
agent distribution as a function of infusion time for the case κw/κg = 1000. Each
image shows the computed distribution after a 6 min time increment. Not surpris-
ingly, the highest concentration is near the infusion catheter, and the concentration
decreases near the outer boundary of agent penetration. It is clear that the in-
fused ﬂuid reaches a high conductivity white matter zone during the ﬁrst time37
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Figure 3.2: Transient evolution of the concentration proﬁle of an infused drug
at time=0, 6, 12, 18, and 24 min. The color represents the nor-
malized concentration (c/co) which ranges from 0 (blue) to 1
(red).
interval. Once infused ﬂuid reaches a high conductivity region, it travels preferen-
tially within that zone.
Fig. 3 illustrates eﬀects of the ratio κw/κg by showing the agent penetration
after 15 min of infusion for three diﬀerent values of the ratio. For κw/κg = 5.9
(left), the eﬀect of the diﬀerence in tissue permeabilities is not substantial, and
the distortion from isotropy is not signiﬁcant. As expected, the highest concentra-
tion is near the infusion catheter, and the concentration decreases near the outer
boundary of agent penetration. For κw/κg = 200 (middle), the ﬂuid that reaches
a white matter tract travels preferentially along the tract without extending a sig-
niﬁcant distance into gray matter adjacent to the white matter tract. The white38
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Figure 3.3: The eﬀect of the ratio of white matter to gray matter perme-
ability on drug distribution for values of κw/κg of 5.9 (left), 200
(middle), 1000 (right)
matter tract acts as a ﬂuid “sink” that entrains a signiﬁcant fraction of the infused
ﬂuid. Because ﬂuid that enters white matter is unlikely to return to gray matter,
the presence of the white matter tracts represents a signiﬁcant challenge for CED
if the target cells are located in gray matter. There are only small diﬀerences be-
tween the agent distribution proﬁles in the middle (κw/κg = 200) and right (κw/κg
= 1000) images, which suggests that once the ratio of permeabilities becomes suﬃ-
ciently large, further increases in the ratio do not strongly aﬀect agent distribution.
Identifying the ranges of parameters over which the agent distributions change is
a key beneﬁt of simulation.
A comparison between simulation and an experimental infusion in the rat brain
is shown in Fig. 3.4. In this case, a ﬂuorescently-labeled dextran (3 kDa) was in-39
fused into the hippocampus of an adult rat. The concentric tissue layers that
characterize the hippocampus are visible in the image on the right. The arrows
indicate the region that is expanded in the middle image. The middle image is
a postmortem photograph of the brain slice showing the infusion point and the
extent of ﬂuorescent compound penetration. The infused dextran is conducted
primarily within one of the more permeable tissue layers, and very little of the
infused agent permeates into the adjoining less permeable layers. The diﬀerence
in permeability between the layers is not known, but a simulation can be used to
estimate it. The image on the left corresponds to the agent distribution proﬁle
computed for the same region taking the ratio of permeabilities to be 100. Al-
though the use of ﬂuorescently-labeled compounds makes a quantitative compari-
son between simulation and experiment diﬃcult, the computed agent distribution
resembles the observed distribution at least qualitatively for the selected ratio of
tissue permeabilities.
3.4 Discussion
As we demonstrated in Chapter 2, at suﬃciently large infusion rates, the local
porosity of the tissue can increase or decrease owing to the stress that the ﬂowing
ﬂuid imposes on the solid phase of the porous medium [27, 35, 29, 58]. Studies
in brain phantom gels [35] with poroelastic properties that resemble those of gray
matter show a local increase in porosity for infusion rates greater than 1 µL/min.
However, the increased porosity was conﬁned to a small region about the catheter.
At a distance of 50 µm from the infusion point, the increase in porosity was 10%
for infusions at 1 µL/min. At high ﬂow rates (>5 µL/min) there is evidence that
tissue adjacent to the infusion site signiﬁcantly compresses, leading to a decrease in40
Figure 3.4: The distribution of 3 kDa dextran (middle) infused into the hip-
pocampus (right) of the rat brain compared to a CFD model
with the same infusion conditions (right).41
permeability [58]. In modeling studies the porosity can be treated as a parameter
and ﬁt to data. Variability in the local porosity near the infusion point can be
tested computationally and compared with infusion data in animal studies, espe-
cially at the start of an infusion when the eﬀect of porosity on ﬂuid distribution is
expected to be greatest.
In this study we have taken the ﬁrst step towards a computational tool to pre-
dict distribution of infused ﬂuids in the brain. First, we determined a critical value
for the ratio of permeabilities between white and gray matter to be 200. While
reports of the values of permeability for white matter are scant, those that have
been reported suggest that κw/κg > 100 [70, 30, 33] is a reasonable assumption.
In data not presented here, we adjusted the magnitude of the permeabilities while
holding the ratio between white and gray matter constant. Somewhat surprisingly,
the magnitudes had no detectable inﬂuence on the distribution, only increasing or
decreasing the magnitude of the pressure. This is a useful result because it is easier
to determine the relative permeability from imaging studies than it is to determine
the absolute value.
We have validated this model by comparing simulation results with an infusion
into a highly heterogeneous feature, the hippocampus, of the rat brain. In this case,
simulations qualitatively predicted the entrainment of 3 kDa dextran (hydraulic
diameter of 1.3 nm [74]) into white matter tracts within in the hippocampus.
The entrainment of ﬂuid into highly permeable features illustrates the futility
of attempting centimeter scale drug penetration in heterogeneous medium like
most brain tumors. These results also support results from clinical trials which
report increased incidence of chemical meningitis in patients with tumors near
white matter and ventricles due to entrainment [24, 15, 14]. A better strategy42
may be to use multiple sources whose strength can be adjusted according to the
anatomy of the targeted tissues. The concept of multiple sources is described in
Chapter 5.
The model presented here assumes symmetry in the third dimension. This
assumption most likely explains the subtle deviation between simulations and in-
fusion data in the hippocampus. The length scales over which tissue properties
vary orthogonal to the computational slice and within the slice are comparable to
each other and to the length scale of drug penetration due to infusion. Therefore,
while the two-dimensional model captures some of key characteristics of pressure
driven ﬂow in the brain, a truly predictive model needs to incorporate the third-
dimension.
3.5 Future Directions
Ultimately, the goal of computational model is to guide clinicians in choosing
catheter placements and infusion conditions that will provide optimal drug cover-
age. To this end we propose a four step process: 1) Develop a three-dimensional
model of the brain that solves the equations for ﬂuid ﬂow and whose physical
properties vary spatially as determined from imaging studies. 2) Assess model
performance by comparing model predictions with imaging of agent infusions in
animal models, and to use comparisons to reﬁne the model and estimate tissue
physical properties. 3) Develop a simulation tool for pre-operative planning that
combines predictions of agent distribution with images from MRI methods. 4) Use
the model to design new delivery strategies that would be diﬃcult to implement
without prior modeling, such as time varying ﬂows and the use of multiple ﬂuid
sources and sinks.CHAPTER 4
FABRICATION AND CHARACTERIZATION OF MICROFLUIDIC
PROBES FOR CONVECTION ENHANCED DRUG DELIVERY
4.1 Introduction
CED involves inserting a small cannula or needle into an aﬄicted area and infusing
of drug or imaging solutions at a speciﬁed ﬂow rate. This cannula is most often
a stainless steel needle ranging from 20 to 32 gauge in size. In prior studies ﬂow
rates ranged from 0.1-10 µL/min and were controlled with an external syringe
pump. At ﬂow rates greater than 1 µL/min, backﬂow of infused solutions up the
outside of the needle shaft has been reported [57]. Apparently, at suﬃciently high
ﬂow rates, the tissue separates from the needle, and injected ﬂuid ﬂows preferen-
tially along the separation. Backﬂow reduces control over drug delivery because
infused solutions can ﬂow out of the brain or into highly permeable white matter
tracts surrounding the infusion site. The separation that allows backﬂow can be
controlled by adjusting the ﬂow rate and the size of the needle [53].
The pressure at the outlet of the cannula or needle often is monitored during
CED infusion. This pressure often rises to unexpectedly large values at the start
of infusion. The large pressure could reﬂect the mechanical response of the tissue
near the infusion point, an artifact in the infusion process, or both. For example, it
is possible that the tip of the needle is partially or fully occluded when it is inserted
into the brain, although some studies suggest the elevated pressure is observed in
the absence of occlusion[75]. Another possibility is that the tissue surrounding the
needle tip is compressed at the start of infusion, which would decrease the hydraulic
permeability of the tissue near the needle and increase resistance to ﬂow[36]. The
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subsequent decrease in pressure may be correlated with a structural change in the
adjacent tissue [76]. It has been suggested that a CED needle or catheter with
ﬂuid outlets along its side, rather than at its tip, could alleviate some of these
problems[77].
Microfabricated devices oﬀer several potential advantages over needles and
catheters for CED. A microfabricated device could be made small to minimize
tissue damage [78], reduce backﬂow, yet rigid enough to penetrate deep into tissue
(∼1 cm). The ﬂuid outlet could be located away from the penetrating edge of the
device to avoid occlusion of the channel. Furthermore, microfabrication oﬀers the
possibility of integrating electrical, mechanical, and chemical sensors with the ﬂuid
delivery system [79, 80, 78]. For example, microﬂuidics have been added to sili-
con microelectrodes to control the local chemical environment during extracellular
recordings in the cortex [81]. Microneedles with on-chip ﬂow meters [82] and pumps
[83] provide ﬂuid ﬂow control and minimize reagent volume. The implantation of
silicon devices has been extensively characterized for cortical neural prosthetics
[84]. Some implanted devices have recorded electrical signals for up to one year in
vivo [85]. Other neuroscience applications for which microﬂuidic devices may be
useful include measuring cerebrospinal ﬂuid ﬂow [86], infusing neurotransmitters
and neurotrophic factors [87, 88], and studying addiction mechanisms [89].
A ﬁrst step in building an integrated microﬂuidic delivery system for CED
is to demonstrate that ﬂuid can be delivered through a microfabricated device
at rates comparable to those for needles and cannulas. This study describes the
microfabrication and testing of a device that can be inserted into brain tissue and
deliver ﬂow rates appropriate for CED (0.1-5 µL/min). The device is designed
to deliver ﬂuid to the caudate nucleus of adult rats for direct comparison with45
previous studies that used needles [7, 57, 53]. Infusions into agarose brain phantoms
and the rat caudate are examined to determine whether higher ﬂow rates can
be achieved, without signiﬁcant ﬂuid reﬂux, with microﬂuidic devices than with
standard needles. In addition, an analytical model is developed to examine the
eﬀect of diﬀusion on the penetration of infused drugs.
4.2 Methods and Materials
4.2.1 Fabrication of microﬂuidic probes
Devices were fabricated using standard micromachining techniques for patterning
silicon and polymer layers. Figure 4.1 shows a schematic of the fabrication process,
which involves a series of patterning, deposition, and removal steps. The ﬁnished
device consists of three parts shown in Figure 4.2: an insertable microprobe with
a cross-section of 100 µm X 100 µm and a length that varies from 2 to 5 mm, a
square handle with dimensions of 2 mm X 2mm X 300 µm, and a protrusion with
a length of 2 mm and a cross-section of 100 µm X 100 µm that can be connected
to external tubing. A detailed fabrication process can be found in Appendix A.
To start the fabrication a silicon dioxide etch mask was deposited on the back
side of a double-sided, polished silicon wafer with a thickness of 300 µm (Figure
4.1(a)). The backside of the wafer was then etched with deep reactive ion etching
to a depth of 200 µm to deﬁne the insert and protrusion thickness (Figure 4.1(b)).
A 2 µm silicon dioxide layer was then deposited on the back side of the wafer using
plasma enhanced chemical vapor deposition (PECVD). This layer acts as an etch
stop when the front side of the wafer is etched in a subsequent step (Figure 4.1(c)).
To form a base layer for the microchannel, a 5 µm thick layer of positive tone46
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Figure 4.1: Summary of fabrication process; a) Deposition and patterning of
silicon dioxide etch mask, b) DRIE of backside silicon, c) Depo-
sition of silicon dioxide etch stop, d) Patterning of photosensitive
polyimide adhesion layer, e) Patterning of sacriﬁcial photoresist
layer, f) Deposition parylene structural layer , g) Evaporation
and patterning of aluminum etch mask, h) Patterning of pho-
toresist etch mask, i) Patterning of parylene by oxygen plasma,
j) DRIE of front side silicon, k) Deﬁnition of channel inlet and
outlet in parylene by oxygen plasma, l) Dissolution of silicon ox-
ide and aluminum in buﬀered oxide etch and release of sacriﬁcial
photoresist in acetone.47
polyimide (Photoneece, Toray Industries, Japan) was spun, patterned, and cured
on the front side of the wafer (Figure 4.1(d)). Next, sacriﬁcial photoresist was spun
on top of the polyimide to form a layer of height 10-15 µm. The wafer was then soft
baked in a convection oven at 90◦C for 30 min. The photoresist was patterned and
developed, leaving photoresist in place to deﬁne the microchannel (Figure 4.1(e)).
The assembly was hard baked at 90◦C for 5 min. The polyimide base layer was then
roughened with an oxygen plasma (400 W, 1 min) to promote adhesion between
polyimide and parylene. A layer of parylene C (Specialty Coating Systems) was
then deposited to a thickness of 5 µm (Figure 4.1(f)).
Following parylene deposition, a 100 nm layer of aluminum was electron beam
evaporated and patterned in the shape of the channels (Figure 4.1(g)). The alu-
minum acts as a mask for etching the inlet and outlet holes of the channel. A
subsequent resist layer was spun and patterned to serve as an etch mask for both
the bulk parylene etch and the silicon deep reactive ion etch (Figure 4.1(h)). Pary-
lene was etched with 150 W oxygen plasma at a rate of 100 nm/min (Figure 1(i)).
The silicon was etched down to the oxide etch stop to deﬁne the insert and protru-
sion geometry (Figure 4.1(j)). Next, the inlet and outlet holes were etched in the
parylene layer using the aluminum etch mask (Figure 1(k)). The oxide etch stop
and aluminum mask were simultaneously removed in buﬀered oxide etch. Finally,
the photoresist was removed from the channels in an acetone bath for four hours
followed by four hours in isopropyl alcohol and twelve hours in deionized water
(Figure 4.1(l)).
This procedure can be used to fabricate channels with heights between 1 and
20 µm and widths between 10 and 100 µm. The channels used in this study had a
height of 10 µm and a width of 50 µm. The length of the channel was 8 mm from48
protrusion to tip.
4.2.2 Experimental Set-Up
Microﬂuidic devices were attached to micropipettes (OD=1 mm, ID=0.58 mm
and OD=2 mm, ID=1.12 mm) using two part epoxy. The micropipette was then
backﬁlled with 0.1% (w/v) Evans Blue, or 1% (w/v) Evans Blue labeled albumin
and inserted into a micropipette holder on a micromanipulator. The micropipette
holder was connected to a programmable pressure injector (World Precision In-
struments PM8000, Sarasota, FL, USA) with low compliance polyethylene tubing.
Compressed high purity nitrogen was used as a pressure source. The injector
maintained a constant pressure at the inlet of the channel. The ﬂow rate through
the devices was determined by measuring the speed of the liquid front in the mi-
cropipette. In some experiments a 30 gauge blunt needle was used in place of the
microﬂuidic device so that a direct comparison could be made between delivery
methods.
Most CED protocols infuse ﬂuid at a constant ﬂow rate, but infusion at con-
stant pressure has distinct advantages here. First, it is easier to manipulate ﬂuid in
microﬂuidic devices by regulating pressure rather than ﬂow rate, especially while
priming a channel that is initially ﬁlled with air. Second, in constant pressure infu-
sion, the pressure proﬁle in the tissue is independent of tissue material properties
(Section 2.6).
4.2.3 Agarose Brain Phantoms
Agarose gels (0.6% w/v) were used as a brain tissue analog to characterize the
delivery from the devices. Flow in agarose at this concentration mimics some49
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Figure 4.2: Electron micrographs of microﬂuidic probe. (a) Parylene mi-
croﬂuidic channel with dimension of 50X10 µm. (b) Pointed tip
of insertable portion of probe. (c) Entire probe with protrusion
for ﬂuidic connection (1), base for handling (2) and tissue pene-
trating insert (3).50
characteristics of pressure driven ﬂow in brain tissue [77]. Agarose powder was
added to Tris-Borate-EDTA (TBE) buﬀer and heated in a microwave oven on high
heat for 90 sec while covered. The hot solution was poured into 100 mm tissue
culture plates and allowed to gel for two hours at room temperature. The devices
were inserted 5 mm into the gels at a rate of 1 mm/sec using a micromanipulator.
A ﬁxed volume (ranging from 10 to 40 µL) of the dye solution was infused into the
gel at pressures of 35, 70, 140, and 210 kPa to achieve ﬂow rates of 0.5, 1, 2, and 3
µL/min. The dye ﬂowed radially outward from the tip of the device and formed an
approximately spherical volume about the device tip. After infusion, which lasted
between 10 and 80 min, the penetration depth was determined by measuring the
diameter of the dyed agarose sphere with calipers.
4.2.4 Animal Studies
Twelve male Sprague-Dawley rats (180-200 g) were used to characterize the perfor-
mance of devices in vivo. Rats were anesthetized with ketamine (100 mg/kg)/xyly-
zine (10 mg/kg) solution via intraperitoneal injection. The head was shaved and
disinfected with butadiene/alcohol/butadiene cotton swabs. An incision was made
and a 1 mm diameter hole was drilled in the skull 3 mm laterally from bregma. The
device was inserted into the brain at a rate of 1 mm/sec with a micromanipulator.
The tissue was allowed to equilibrate mechanically for 3 min. which is much longer
than the time constant for polymer relaxation in the brain [29]. Then, a solution
Evans Blue labeled albumin was infused at 35, 70, and 140 kPa into the caudate
putamen to achieve ﬂow rates of approximately 0.5, 1, 2, and 3 µL/min. The ﬂow
rate was determined by measuring the ﬂuid speed in the micropipette. After 5 µL
of the Evans Blue labeled albumin solution was infused, the device was vented to51
atmosphere and promptly removed. The animals were immediately sacriﬁced by
carbon dioxide inhalation and the brains were removed and ﬂash frozen in -70◦C
hexane. The brains were sectioned into 25 µm slices on a cryostat. Every ﬁfth slice
was collected for image analysis. All procedures were done in accordance with the
regulations of the Yale University Institutional Animal Care and Use Committee.
4.2.5 Image Analysis
Frozen sections of brain tissue sections were imaged using a stereoscope and CCD
camera. Images were captured as RGB 8-bit TIFF ﬁles using StreamPix software
(Norpix Inc., Montreal, Canada). To determine the penetration of the albumin
the RGB ﬁle was broken into red, green, and blue planes using a Matlab script.
Each plane consists of 480 X 640 pixels of intensity data on a scale of 0-255. Blue
plane pixels were normalized by dividing each individual pixel by the total pixel
intensity of all three colors, BN = B/(R + G + B). In RGB format, white light
33.3% red, 33.3% green, and 33.3% blue. Therefore, a pixel was considered to have
a dominant blue intensity if the value of BN was greater than 0.333. Pixels with
values greater than 0.333 were assigned a pixel value of zero, and all pixels with
values less than 0.333 were assigned a value of one. The result was binary image
where zero is black and one is white. To minimize background noise an erosion
operation was applied to each image. The erosion operation speciﬁed that if more
than four of a black pixel’s eight neighbors were white, then that pixel was changed
to white. The topology of the thin slices left artifacts in the image that appeared
as isolated white pixels within large black, or dyed, areas. A dilation operation
was used that speciﬁed if more than four of a white pixel’s eight neighbors were
black, then that pixel was changed to black. After image processing, the area of52
each slice was calculated by summing the number of black pixels. The Analyze
Particles tool in ImageJ software (National Institutes of Health, Bethesda, MD)
was used to calculate the area of each dye spot and the major and minor axis of
an ellipse ﬁt to the spot. Because we were interested in examining drug delivery in
gray matter, only dye in the gray matter was considered for calculating the aspect
ratio between the major and minor axis.
This method does not measure dye concentration, but instead determines only
a threshold concentration. Some of the images from each animal were also imaged
by epiﬂuorescence using a rhodamine ﬁlter to estimate the threshold concentra-
tion. A two-dimensional surface plot of the intensity proﬁle of the ﬂuorescent
images was compared to processed stereoscope images. Assuming that intensity
is proportional to concentration, the threshold concentration was ∼ 60% of the
injected concentration.
4.2.6 Model of Molecular Transport
The penetration distance of an infused compound can be estimated by assuming
that convective and diﬀusive transport take place in parallel [29]. The character-
istic time for diﬀusion, τD is,
τD =
r2
D
(4.1)
where D is the diﬀusion coeﬃcient of the infused molecules in the porous medium.
The characteristic time for convection, τC is
τC =
Z r
a
dr0
v(r0)
=
φ
3Poκa
(r
3 − a
3) (4.2)53
To estimate the penetration distance after infusion over some time T, the inverse
characteristic times for diﬀusion and convection are summed as follows
1
T
=
1
τD
+
1
τC
(4.3)
The value of r that satisﬁes eq. (4.3) is an estimate of the penetration distance R.
The Peclet number Pe = τD/τC gives the relative importance of convective
transport compared with diﬀusive transport. For infusion into a porous medium,
Pe is a maximum at the infusion point and decreases with distance from the infu-
sion point. In the limit of inﬁnitely large Pe, convection dominates ﬂuid transport
everywhere and diﬀusion can be neglected, which yields the convection-dominated
penetration distance RC as a function of time T
RC =

3QT
4πφ
1/3
(4.4)
This model is well suited for infusions into gels where there are no elimination
mechanisms. The eﬀect of elimination has been treated by Morrison et al. for a
rigid pore model of constant pressure infusions[26].
4.3 Results
4.3.1 Device characterization
Constant pressure infusions were controlled by a pressure injector, which sets the
pressure upstream of the microchannel to a desired value. However, there is a sig-
niﬁcant pressure loss over the length of the microchannel, which must be taken into
account to ﬁnd the infusion pressure, Po, at the microchannel exit. To determine
this pressure loss as a function of ﬂow rate, ﬂow rates in the microchannel were54
measured for several injector pressures with the exit of the microchannel outlet
immersed in a water reservoir (zero gauge pressure). A linear relationship between
ﬂow rate and injector pressure was found, which is expected because ﬂow in the
microchannel is laminar. The pressure drop ∆P between the injector and the mi-
crochannel exit was found to be ∆P (in kPa) = 70.0Q (in µL/min). Therefore,
during an infusion experiment, Q was measured and this formula was used to
ﬁnd ∆P, which was then subtracted from the injector pressure to determine the
pressure at the channel outlet, Po.
4.3.2 Distributions of infused compounds and backﬂow
The infusion of dye into agarose gels was studied for injector pressures of 7, 35,
70, 140, 210, and 310 kPa, which corresponded to infusion ﬂow rates of 0.08, 0.4,
0.8, 1.7, 2.9, 4.5 µL/min, respectively. In every case, the infusions resulted in
spherically symmetric dye distributions about the exit of the microchannel. There
was no visual evidence of backﬂow at any of these injector pressures. Figure 4.3
shows a linear relationship between Q(a)/4πa and Po; according to eq. (2.19),
the slope of this line gives an apparent hydraulic conductivity for 0.6% agarose
of 2.05X10−12 m2/Pa-s. Even at the lowest injector pressure (7 kPa), penetration
of the dye was observed immediately, suggesting that the probe outlet was not
occluded. There was no evidence of a pressure barrier to initiate ﬂow. In contrast,
for infusion through a blunt 30 gauge needle inserted into the gel in the same
manner, the pressure had to exceed 11 kPa before there was evidence of ﬂow. To
compare the performance of the microfabricated device with that of a needle, the
injector pressure was increased in stages until the onset of backﬂow was observed.
For the microﬂuidic device at an insertion depth of ﬁve millimeters, the backﬂow55
was observed when pressure was increased to 310 ± 8 kPa (n=10) corresponding
to a ﬂow rate of 4.5 µL/min. For a 30 gauge needle backﬂow was observed when
the pressure was increased to 20 kPa ± 4 (n=10) corresponding to a ﬂow rate of
0.41 µL/min.
The device was inserted three millimeters laterally from bregma into the cau-
date of the rates to a depth of ﬁve millimeters (Figure 4.4(a)). The infusion of
dye was studied for injector pressures of 35, 70, and 140 kPa (Figure 4.4(b-d)). In
these cases the infusions resulted in dye distributions that were nearly elliptical
except in one case at 140 kPa (Figure 4.4(d)). Figure 3 shows that the relationship
between ﬂow rate and pressure at the outlet of the channel, Po, was linear, and
a comparison of data with eq. 8 yielded a value of 5.63X10−12 m2/Pa s for the
apparent hydraulic conductivity of gray matter in the caudate putamen.
The shapes of the dye distributions in the rat brain depended on the injector
pressure. Figure 4.5 shows processed images of the dye distributions for the three
values of the injector pressure. Each montage contains coronal slices from a single
brain at a given pressure. The slices are separated by 0.5 mm. Their distances
from bregma are given in millimeters; positive numbers refer to the slices anterior
to bregma and negative numbers refer to slices posterior to bregma.
At an injector pressure of 35 kPa, the distribution of dye within each coronal
section was slightly non-spherical (Figures 4.4(b) and 4.5(a)). At 70 kPa (Figures
4.4(c) and 4.5(b)) and 140 kPa (Figures 4.4(d) and 4.5(c)) the distributions were
more elongated. Single factor analysis of the variance (ANOVA) was performed
on both the total volume of dye in the gray matter and the aspect ratio of the
distribution at the infusion site (3 mm lateral from bregma). Table 4.1 and 4.2
show a summary of the ANOVA results for an alpha value of 0.05 for volume and56
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Figure 4.3: The apparent hydraulic conductivity was calculated using
Darcy’s Law in radial coordinates, where Po = (Q(a)/4πa)κ,
for injection into 0.6% agarose () or brain (). The x-axis
is the pressure at the tip of the device. The injector pressure
upstream from the device was 7-210 kPa. The ﬂow rate was es-
timated by measuring the time it took for 1 µL of volume to be
expelled through the device into the gel or tissue. Each symbol
represents one infusion. There were 5-20 measurements taken for
each infusion depending on the infused volume and the error bars
represent one standard deviation from these measurements. Best
ﬁts of eq. (2.19) to experimental data are shown by dashed lines.57
(a)
(b) Pinject=35kPa (d) Pinject=140kPa (c) Pinject=70kPa
Figure 4.4: (a) The microﬂuidic probe with attached ﬂuid reservoir was in-
serted 3 mm laterally from bregma to a depth of 5 mm into the
caudate nucleus (Top). (b)-(d)An overlay of the processed data
on a cartoon of the insertion site illustrates the pressure depen-
dence of the dye distribution at injection pressure of 35, 70, and
140 kPa.
aspect ratio, respectively. In both cases there were statistically signiﬁcant (p<0.05)
diﬀerences between the low, medium, and high pressure groups. However, there
was not a statistically signiﬁcant diﬀerence in the aspect ratio beyond the infusion
site. This result suggests that asymmetrical distribution was limited to tissue
immediately adjacent to the device.58
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Figure 4.5: Distribution of Evans blue labeled albumin in the caudate of
rats at infusion pressures of (a) 35 kPa, (b) 70 kPa, and (c) 140
kPa. Each coronal slice is labeled by its position with respect to
bregma (β) in millimeters. The infusion site is at 0.0 mm from
bregma.59
Table 4.1: Analysis for the variance of volume of dye in the gray matter
between low (35 kPa), medium (70 kPa), and high (140 kPa)
injector pressures.
Groups Count Sum Average Variance
Low Pressure 3 7.6 2.5 0.11
Medium Pressure 3 8.3 2.8 0.17
High Pressure 3 11.4 3.8 0.01
Source of Variation SS df MS F P-value F crit
Between Groups 3.5 2 1.8 18 0.02 9.6
Within Groups 0.3 6 0.10
Total 3.8 8
Evidence of backﬂow was found in one of three cases for an injection pressure
of 140 kPa but in no cases for 35 kPa or 70 kPa. The crescent-shaped distributions
in Figure 4.5(c) are indicative of backﬂow. In this case, the infused dye migrated
into the white matter of the corpus callosum immediately above the caudate as
a result of backﬂow along the outside of the microchannel. Once in the white
matter, the dye then ﬂowed in anterior and posterior directions. Backﬂow in this
case may have been caused by a poor insertion, which can increase the likelihood
of backﬂow [77]. During curing of the epoxy, occasionally the device becomes
sightly misaligned with the micropipette that holds it. In this event the device is
not exactly perpendicular to the surface as it is inserted, which can lead to tissue
tearing and backﬂow.
Owing to the small size of the rat brain, dye reached white matter even in the
absence of backﬂow. The caudate putamen is the largest area of homogeneous
gray matter. It is roughly spherical with a diameter of approximately 3.0 mm60
Table 4.2: Analysis for the variance of the aspect ratio at 0 mm from bregma
between low (35 kPa), medium (70 kPa), and high (140 kPa)
injector pressures.
Groups Count Sum Average Variance
Low Pressure 3 3.6 1.2 0.004
Medium Pressure 3 4.91 1.6 0.068
High Pressure 3 4 1.3 0.002
Source of Variation SS df MS F P-value F crit
Between Groups 0.32 2 0.16 6.4 0.03 5.1
Within Groups 0.15 6 0.025
Total 0.47 8
and is surrounded by a white matter envelope consisting of the corpus callosum
[73]. Infused albumin reached the anterior forceps of the corpus callosum at a
penetration distance of 2 mm and subsequently ﬂowed several millimeters in the
anterior direction. This projection is clearly seen in Figure 5(b) which shows dye
up to 4 mm anterior to the infusion site. Such extensive penetration is unlikely in
gray matter, but it could occur by transport through the high permeability tracts
of white matter.
4.3.3 The eﬀect of diﬀusion on penetration distance
The potential advantage of CED is that penetration into tissue can be enhanced
by convection compared with the penetration obtained by diﬀusion in controlled
release. Convection dominates diﬀusion near the microchannel tip, but the infu-
sion velocity decays as 1/r2 where r is the distance from the tip. If the infused
drug penetrates suﬃciently far from the infusion point, then its transport may be61
dominated by diﬀusion at its farthest penetration. The distance where this occurs
depends not only on the infusion rate, but also on the diﬀusivity of the injected
molecules.
To show how diﬀusion can aﬀect the penetration distance in CED, infusions
into agarose were compared for two infused molecules: a small water soluble mole-
cule (Evans Blue) and a large globular protein (albumin). Infusions of various
durations were performed and the volume of gel containing dye Vd was measured
and compared with the known volume of ﬂuid Vi that was infused. Figure 4.6
shows the ratio Vd/Vi as a function of infusion time. In the absence of diﬀu-
sion, corresponding to an inﬁnitely large Peclet number everywhere throughout
the ﬂow, the ratio Vd/Vi would equal the inverse of the porosity 1/φ regardless of
the infusion time. However, the data show that the ratio depends on infusion time,
which indicates that diﬀusion aﬀects the penetration distance. The ratio is larger
and shows greater sensitivity to infusion time for Evans Blue, which is expected
from eq. (11) based on its larger diﬀusivity (D=2.0X10−6 cm2/sec, Stokes-Einstein
equation, molecular radius from Markou et al.[90]) compared with the diﬀusivity
of albumin (D=8.3X10−7 cm2/sec in 0.3% agarose [91]). Data for both compounds
were compared with the model described in section 2.6 by using eq. (2.25) to
estimate the penetration depth for the appropriate experimental parameters. The
result shown in Figure 6 shows good agreement between the model and the data
over a wide range of infusion times. The coeﬃcient of multiple determination (R2)
was 0.70 for Evans Blue and 0.83 for albumin.62
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Figure 4.6: Volume distributed:volume infused of Evans Blue () and albu-
min () into 0.6% agarose at an infusion pressure of 5 kPa and a
comparison to model predictions (–). Each data point represents
a separate infusion. The model accurately predicts the time de-
pendent Vd :Vi observed with infusion of Evans Blue (R2=0.70)
compared to the relatively time insensitive results obtained dur-
ing infusion of albumin (R2=0.83).63
4.4 Discussion
The microfabricated devices described here have several advantages over larger nee-
dles for CED. The devices can deliver liquids at ﬂow rates comparable to those in
CED with needles with reduced backﬂow that often hampers ﬂuid delivery through
needles [77, 53]. In principle, devices can be fabricated for speciﬁc anatomical
geometries with the option of placing several delivery outlets on a single device.
In addition, other components can be incorporated into microfabricated devices,
including recording/stimulating electrodes, pumps, valves, and ﬂow meters.
Infusing at constant pressure rather than at constant ﬂow rate has important
consequences on the pressure and stress distributions in the tissue. For constant
pressure infusion, the pressure proﬁle in the tissue is independent of the tissue’s
material properties (eq. (6)), including its hydraulic conductivity. Furthermore,
Netti et al. showed that for constant pressure infusion into a poroviscoelastic
material, the radial and circumferential stress components also are independent of
the hydraulic conductivity [29]. In contrast, the pressure and stress components
are strongly aﬀected by the hydraulic conductivity for constant ﬂow rate infusion.
If suﬃciently high levels of stress incite apoptotic or necrotic signalling cascades in
neurons or glial cells [92], then knowing the stress proﬁle even when the hydraulic
conductivity is uncertain is an advantage of constant pressure infusion.
There is a wide range of values reported for hydraulic conductivity in tissues
and gels (from 1X10−11 to 1X10−16 m2/Pa-s) [22, 36, 27, 92, 29]. Our value of
2.05X10−12 m2/Pa-s for gray matter in the rat agrees reasonably well with Basser’s
estimate of 5X10−12 m2/Pa-s [27]. However, the conductivity of elastic or viscoelas-
tic porous media depends on deformation of the media. For example, Deen and
Johnson show that the conductivity of agarose decreases in uniaxial ﬂow owing to64
compression of the void space in the gel [36]. In a radial source ﬂow like the one
presented here, the magnitudes and signs of the radial and circumferential stress
components determine whether the tissue is dominated by compression or tension.
Zhang et al. found an increase in permeability with respect to infusion pressure in
radial ﬂow in ﬁbrosarcomas under constant pressure infusion (2-16 kPa) of albu-
min [40]. For constant pressure infusion with our microﬂuidic probes, the apparent
hydraulic conductivity did not depend on ﬂow rate in agarose or in brain tissue.
However, the apparent hydraulic conductivity is calculated based on the pressure
and ﬂow rate at one point, the infusion site. To distinguish local conductivity
changes in response to ﬂow, one would need to measure pressure as a function
of distance [22]. The apparent value we report may overestimate the actual con-
ductivity of a poroelastic medium since dilation is expected to be greatest at the
infusion site, leading to increased porosity and higher conductivity there.
Several investigators have observed an increase in pressure followed by a pre-
cipitous decrease to a steady-state value at the beginning of constant ﬂow rate
infusions. This result has been attributed to the elasticity of brain tissue [77],
the opening of ﬂuid channels in the extracellular matrix [40], and simply occlusion
of the needle tip [4]. Our observations are consistent with the last explanation.
During constant pressure infusion into 0.6% agarose using a blunt needle we found
that a critical pressure (∼10 kPa) was necessary to observe convective ﬂow. When
the pressure was increased to values only slightly larger than this critical pressure,
a burst of dye was suddenly infused followed by signiﬁcant backﬂow at insertion
depths of 5 mm. The microﬂuidic devices did not exhibit any pressure increases
during infusion. Infusion is observed immediately at the start, regardless of injector
pressure.65
The size of the delivery device for CED aﬀects the maximum allowable infusion
rate without backﬂow for a given insertion depth. A previous study of infusions
of four microliters of albumin through a 32 gauge needle (OD=0.228 mm) into
the caudate of rats showed that the maximum ﬂow rate without backﬂow into
the corpus callosum was 0.5 µL/min [57]. Lonser et al. infused the brainstem
of primates with a 32 gauge needle at ﬂow rates of 0.25-1 µL/min [9] without
backﬂow. Our microﬂuidic probes achieved ﬂow rates of 1.0 µL/min (70 kPa
injector pressure) without backﬂow. At 2.0 µL/min (140 kPa injector pressure)
we found a crescent shape distribution (Figure 4c) indicative of backﬂow into the
corpus callosum in one animal. However, backﬂow in this case was most likely due
to a poor insertion.
Using scaling arguments, Morrison et al. found xm = constantQ0.6r0.8
c , where
xm is the axial length of backﬂow, Q is the ﬂow rate, rc is the catheter radius, and
the constant is related to the physical properties of the porous medium [53]. For in-
fusions into the gray matter of rats they found xm(cm) = 11.4Q(µL/min).6rc(cm).8.
Applying this formula to the microﬂuidic probes using a hydraulic radius of 0.05
mm (rc = area/(perimeter/2)) gives a maximum ﬂow rate of 1.6 µL/min which
is similar to our observations.
Human clinical trials for the treatment of malignant gliomas with oﬀ-the-shelf
catheters have shown promise in treating tumors and resection cavities [24]. The
large size of the targeted tumors (∼ 1-5 cm) and kinetics of the cytotoxic agents
require long infusion times (2-4 days) and high ﬂow rates (5-10 µL/min). Applying
Morrison’s scaling relationship for gray matter to these high ﬂow rates with a 32
gauge needle gives backﬂow distances of one to two centimeters. A microﬂuidic
device could be designed using the process described in this study to have a hy-66
draulic radius as small as 10 µm. If the scalings hold down to this size, such a
device would result in backﬂow distances of only a few millimeters even at ﬂow
rates up to 10 µL/min.
4.5 Conclusions
Microﬂuidic devices have been fabricated that are capable of delivering liquids at
relevant ﬂow rates for convection enhanced drug delivery. The small size and geom-
etry of these devices oﬀers potential advantages over traditional needle/catheter
infusion protocols. The orientation of the channel inlets on the top of the device
inhibit channel occlusion during insertion into tissue. The use of a small chan-
nel operating under constant pressure infusion leads to stress ﬁelds that are local
(∼100 µm) and independent of hydraulic conductivity which helps minimize back-
ﬂow and produce spherical distributions of infused ﬂuids, at least in porous media.
Fluid distribution into the caudate of rats showed slight asymmetry. In direct com-
parison with needles in agarose brain phantoms, microﬂuidic devices could operate
at ten times the ﬂow rate before inducing backﬂow out of the brain phantom at
a ﬁve millimeter insertion depth. Similarly, in vivo infusions into the caudate of
rats were tolerated at ﬂow rates four times higher than those previously reported.CHAPTER 5
MULTIPOLE FLOWS FOR CONVECTION ENHANCED DRUG
DELIVERY
5.1 Introduction
As outlined in the previous chapters, perhaps the greatest challenge for CED is con-
trolling the distribution of infused agents in heterogeneous and anisotropic regions
of the brain and tumors. This is important not only for targeting diseased tissue,
but also for prohibiting penetration of potentially toxic levels of drugs into healthy
tissue which has been identiﬁed as a complication during CED clinical trials [24].
Clinical applications of CED involve the insertion of one or more catheters, all of
which are used to infuse ﬂuid into the brain. The ﬂuid ﬂows radially outward from
each catheter, and the details of the ﬂow ﬁeld are dictated by the magnitude of
the applied pressure gradient and the properties of the porous medium. This pro-
tocol provides limited control over the direction of ﬂuid streamlines, which makes
it diﬃcult to guide ﬂuid toward aﬀected tissue. Furthermore, it guarantees that
a signiﬁcant portion of the infused ﬂuid will ﬂow through healthy tissue without
any therapeutic beneﬁt.
An alternative strategy is to deploy catheters at diﬀerent locations for simul-
taneous ﬂuid infusion and withdrawal, that is, distributed ﬂuid sources and sinks,
generating a pressure ﬁeld that forces ﬂuid to ﬂow in preferred directions and con-
ﬁnes the infused ﬂuid to speciﬁc regions of therapeutic interest. A similar strategy
is commonly used on a much larger length scale in secondary and tertiary extrac-
tion of petroleum [93]. A number of source (infusion) and sink (withdrawal) wells
are arranged spatially to optimize recovery of displaced oil. The potential ﬂow
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that exists around the sources and sinks is sometimes called multipole ﬂow after
the mathematical technique of multipole expansion to determine leading order be-
havior of a distribution of charges. These multipole ﬂows could be a helpful in
controlling the penetration and distribution of infused drugs.
Koplik and colleagues conducted a series of studies to describe the distribution
of ﬂuid transit times in multipole reservoir ﬂows in a homogeneous porous media
[94, 95, 96, 97]. In two- [95, 96] and three-dimensional [97] geometries there exists
a power-law decay in the transit time which depends on a given tracer’s streamline.
For example in a dipole, a tracer that follows a streamline directly from the source
to the sink has a fast transit time. A tracer that is released in the opposite
direction has a much longer transit time. A set of tracers released at all angles
from a source samples the entire physical space of a closed system. From the
transit time distribution of all of these tracers, qualitative information about the
size and structure of a porous medium can be determined [95].
In this chapter we explore the feasibility of using multipole ﬂow in the brain.
Analytical and computational models were developed based on potential ﬂow in
a three-dimensional isotropic porous medium using the material constraints and
dimensions of the human brain. We used the models to consider the eﬀects of ﬂow
rate, elimination mechanisms, and diﬀusion that are relevant for infused mole-
cules in CED protocols. The case of stratiﬁed medium with two layers of diﬀerent
permeability was used to explore the possibility of using multipole ﬂows to di-
rect infused drugs away from high permeability tracks. Multichannel microﬂuidic
probes were fabricated and tested in various multipole conﬁgurations in a hydro-
gel brain phantom. We discovered a diﬃculty of withdrawing ﬂuid from a point
source in a poroelastic media and fabricated a novel line-sink microﬂuidic probe69
as a possible solution.
5.2 Materials and Methods
5.2.1 Calculation of solutions to Laplace’s equation
In section 1.2.1 we derived the steady-state pressure distribution (eq. 2.17) and
velocity ﬁeld (eq. 2.17) for a homogeneous, isotropic porous medium. The steady-
state solutions satisfy Laplace’s equation and, thus, the ﬂow is irrotational. Since
the solution to the Laplace equation is linear, we can use Green’s functions to
calculate the pressure at any point in a domain with any number of pressure
sources and sinks. The Green’s function of any equation is deﬁned as the solution
to the equation when the inhomogeneous term is a delta function. For Darcy’s
law:
−κ∇
2P = δ(r) (5.1)
In spherical coordinates the three-dimensional delta function has the form of ﬂow
from a constant pressure sphere in the limit of the sphere radius (a) approaching
zero:
P(r) =
Poa
r
(5.2)
G = lim
a→0,Po→1
P(r) =
1
r
(5.3)
where Po is the infusion pressure. The physical signiﬁcance of the Green’s function
is that it determines the pressure ﬁeld at one point in space when there is a point
source of pressure at another point in space.
P =
Poa
|r − r1|
= PoaG(r − r1) (5.4)70
The pressure ﬁeld due to an array of point sources is calculated by superimposing
the corresponding Greens functions::
P =
X
i
Poa
|r − ri|
(5.5)
where ri is the position of pressure sources and sinks.
The Laplace equation and Green’s function solutions can also be applied to
a composite porous medium with layers of dissimilar permeabilities. Consider a
one-dimensional porous medium where the permeability is κ0 for x > 0 and κ00 for
x < 0. Laplace’s equation and the appropriate boundary conditions are given by
∇
2P
0 = 0, x > 0 (5.6)
∇
2P
00 = 0, x < 0 (5.7)
P
0 = P
00, x = 0 (5.8)
κ
0∂P 0
∂x
= κ
00∂P 00
∂x
, x = 0 (5.9)
Composite porous medium calculations were made on a two-dimensional ﬁnite
diﬀerence grid using center-diﬀerence scheme to calculate the pressure ﬁeld:
Pi,j = 1/4(Pi−1,j + Pi+1,j + Pi,j−1 + Pi,j+1) (5.10)
Grid points at corners and edges of the solution grid boundary were subject to
a zero pressure boundary condition. A momentum balance on a horizontal line
at y=0 which separates the two layers of the composite yields the following dis-
cretization scheme that satisﬁes the boundary conditions (eq. 5.9):
Pi,j =
κ00Pi−1,j + κ0Pi+1,j + (κ0 + κ00)Pi,j−1/2 + (κ0 + κ00)Pi,j+1/2
2κ0 + 2κ00 (5.11)71
We assume the permeability at the interface is the arithmetic average of the per-
meability of the two layers. Equations 5.10 and 5.11 were used to populate a
coeﬃcient matrix (C) and solution (S) matrix representing a system of linear alge-
braic equations. The solution to pressure ﬁeld was calculated by multiplying the
inverse of the coeﬃcient matrix by the solution matrix (P=C−1S)
5.2.2 Tracer transport and elimination
The feasibility of using multipole ﬂow for drug delivery depends on the infusion
conditions and material properties of the tissue, and on the physical properties and
elimination mechanisms of the infused drug molecule. The concept of a tracer par-
ticle is useful for evaluating the transport characteristics under these constraints.
Here, we consider the release of tracer particles distributed symmetrically about
the pressure source, and we follow the motion of the tracer particles along stream-
lines dictated by the multipole ﬂow ﬁeld. The tracer particle must satisfy the
transport equation:
∂c
∂t
+ v(r) · ∇c = D∇
2c − kec (5.12)
where c is the concentration, D is the dispersion coeﬃcient, and ke is the ﬁrst-
order elimination constant. Solving the transport equation for a radial source ﬂow
is diﬃcult because the velocity spans three or four orders of magnitude, making
the transport equation nearly hyperbolic at high velocities and nearly parabolic at
low velocities. To numerically approximate the solution to eq. 5.12 would require
an adaptive grid that uses diﬀerent methods to solve the equation in diﬀerent ﬂow
regimes. Such a treatment is beyond the scope of this study. However, we can still
approximate the eﬀects of dispersion and elimination by making a few simplifying
assumptions.72
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Figure 5.1: The radially dependent Peclet number as a function of diﬀusivity
for small molecules (10−10), globular proteins (10−11), and linear
macromolecules (10−12) in brain tissue.73
First, we consider the case of a divergent ﬂow from a single pressure source. To
estimate the Peclet number for this ﬂow, we adopted in section 1.2.6 an assump-
tion commonly used in reaction engineering–that diﬀusion and convection are two
independent events happening in parallel. Figure 5.1 shows the Peclet number as
a function of distance from a source for three molecules whose diﬀusivities span
two orders of magnitude. Convection dominates (Pe>10) up to a distance of 1 cm
from the source for all three molecules. Therefore, we will neglect the diﬀusion
term in the transport equation and only consider elimination and convection.
At steady-state and in the convective limit, the transport equation simpliﬁes
to
v(r) · ∇c = −kec (5.13)
which has an analytical solution in an axisymmetric three-dimensional geometry
of
c/co = exp

−
4πker3
ss
3Q

(5.14)
where co is the concentration of the infused drug solution and rss is the penetration
distance at steady-state. If we further assume that the pharmacologically relevant
concentration is c/co = 0.5, and deﬁne the half-life as t1/2 = ln(2)/ke, then eq.
5.14 can be reexpressed as
rss =

−
3Qt1/2
4πφ
1/3
(5.15)
Equation 5.15 states that for a ﬁxed ﬂow rate the penetration of a molecule is
limited by its elimination constant and that infusing for any time greater that its
half-life will not result in further penetration.
Koplik and colleagues have used a grid-free random walker to characterize trans-
port in reservoir ﬂows [95, 97]. We can adapt parts of this method along with our74
results from simple source ﬂows to gain insight into how drug molecules would
behave in multipole ﬂows in the brain. Consider a random walker that follows a
displacement rule:
∆r = v(r)∆t + n(6∆t)
1/2 (5.16)
where n is a unit vector of random orientation. Now, rather than using eq. 5.16
to calculate displacement, we assume the convective limit and that tracers follow
streamlines. We can check the validity of this assumption by comparing the ﬁrst
and second terms of eq. 5.16 for a given time step. The ratio of these two terms
is essentially a local Peclet number. If local Peclet number is greater than one,
then the tracer particle will stay on or close to the streamline. If the local Peclet
number is less than one, then there is a possibility that the tracer particle will
jump streamlines. The time step is chosen so that the maximum displacement for
a given step is at most 1% of the distance between the source and sink. A second
constraint on tracer displacement is elimination. The tracer particle can move no
further once the transit time equals the half-life of the molecule.
The algorithm for measuring tracer transport can be summarized by the follow-
ing steps: 1) The pressure ﬁeld is determined by superposition of Green’s function
solutions for an array of point sources and sinks. 2) Four hundred tracer particles
are released from a sphere around the source. 3) The displacement of the tracer for
a given time step follows the streamlines. 4) At each position a local Peclet number
is calculated to verify that convective transport is dominant. 4) The transit time
for tracer particles from source to sink must be less than the half-life.75
5.2.3 Fabrication of microﬂuidic probes
Microﬂuidic probes were fabricated using the procedure outlined brieﬂy in section
1.2.1 and described completely in Appendix A. A ﬁve-spot probe consisted of three
parallel shanks 5.8. The outer shanks each contained two ﬂuid channels, while the
middle shank contained one ﬂuid channel. The outer two shanks had a width of 150
µm, a height of 100 µm, a length of 7 mm, and carried two channels. One channel
had an outlet that was 5 mm downstream from the base of the device, while the
other channel had an outlet that was 7 mm downstream from the base of the device.
The middle shank was 6 mm long and had one channel with its outlet near the
penetrating tip. The middle channel was glued into a micropipette as described in
section 1.2.1. The other four channels were glued to ﬂexible polyimide tubing with
an inner diameter of 250 µm (Small Parts Inc.). The pressure in all ﬁve channels
was controlled by a programmable pressure injector (World Precision Instruments
PM8000, Sarasota, FL, USA).
A line-sink probe was fabricated with the exact geometry of the single channel
devices described in section 1.2.1, except instead of a single outlet, these devices
had an array of 10 µm diameter holes spaced 100 µm apart over 3 mm 5.2.
5.2.4 Stratiﬁed brain phantoms and multipole protocols
A stratiﬁed brain phantom was developed with a high permeability (0.6% agarose)
layer sandwiched between two low permeability (2% agarose) layers. Agarose was
dissolved in TBE buﬀer in scintillation tubes immersed in a 90 ◦C water bath.
The ﬁrst low permeability layer was poured into a 100 mm tissue culture dish and
allowed to gel for one hour at room temperature. Next, the high permeability
layer was poured on top of the ﬁrst layer and allowed to gel at room temperature.76
Figure 5.2: Line sink microﬂuidic probe with 10 µm holes spaced 100 µm
apart.77
Finally, the second low permeability layer was poured on top of the other two layers
and allowed to gel at room temperature. The transition between layers was not
abrupt, because each time a hot agarose solution was poured onto a layer that had
already gelled, a portion of the gelled layer melted and re-gelled, forming a gradual
transition between the adjacent layers. This transition zone was characterized by
measuring the permeability using eq. (2.19). The bottom and top layers were 3
mm in height and the middle layer was 2 mm in height. Attempts to make a 1
mm middle layer failed. It melted when the top layer was poured.
Microﬂuidic probes were lowered into the brain phantoms at a rate of 2 mm/sec
using a piezoelectric motor attached to a 3-axis micromanipulator. Five-spot
probes were situated so that channel outlets would lie either completely in a low or
high permeability layer or at the interface between two layers. A constant pressure
was applied upstream and the ﬂow rate was measured in graduated micropipettes.
The hydraulic permeability of each zone was determined by a least squared ﬁtting
to equation 2.19. Evans Blue labeled albumin was infused at 35 to 140 kPa and
water from gel was withdrawn at -10 to -70 kPa. Dye distribution was captured
using a digital camera (Nikon CoolPix 9500) at a resolution of 2048 X 1536 pixels.
5.2.5 In vivo characterization of line-sinks
Line-sink probes were tested in the cortex and striatum of adult rats following the
protocol outlined in section 4.2.4. Brieﬂy, probes were inserted at a depth of 2
mm for cortical withdrawal and 5 mm for striatum withdrawal using a manipu-
lator on the stereotactic frame at an insertion rate of approximately 1 mm/sec.
Withdrawal pressures of -10 to -70 kPa were applied and ﬂow rates were measured
in a graduated pipette.78
A second set of withdrawals were attempted in the striatum of rats who had
undergone enzymatic degradation of their ECM. Ten microliters of Streptomyces
hyaluronidase (1000 U/mL) was infused into the striatum of adult rats 3 mm
from bregma and at a depth of 5 mm using single channel microﬂuidic probes
4.3. Following infusions the scalp was closed with surgical staples and the animal
was given drinking water containing 0.15 mg/ml of ibuprofen. After 24 hours
of digestion, the animal were anesthetized and placed back into the stereotactic
frame. A second hole was drilled 1 mm anterior from the ﬁrst hole and the line-sink
probe was inserted. Withdrawal pressures of -10 to -70 kPa were applied and ﬂow
rates were measured in a graduated pipette.
5.3 Results
5.3.1 5-spot ﬂows in homogeneous porous media
For models of homogeneous porous media we applied the analytical Green’s func-
tion solutions to a ﬁve-spot conﬁguration (Figure 5.3). The ﬁve-spot conﬁguration
consists of a single pressure source of strength +4 surrounded by four equidistant
sinks with strengths -1. This choice of strengths yields a net zero “charge” for the
system and ensures that all of the ﬂuid that emanates from the source is withdrawn
from one of the sinks. The streamlines are calculated by the stream2 function in
Matlab. We used the hydraulic permeability (5 X 10−12 m2/Pa s) and porosity
(0.2) of gray matter as a baseline for calculations. The source-sink distance is 5 mm
to reﬂect a targeted tissue region of 1 cm. The infusion pressure at the source was
set to 30 kPa, corresponding to a ﬂow rate of approximately 5 µL/min which was
determined as the maximum ﬂow rate that does not cause damage to surrounding79
Figure 5.3: 5-spot pressure proﬁle for an infusion pressure of 30 kPa and
withdrawal pressure of 7.5 kPa at sinks a radial distance of 5
mm from the source.
tissue [58]. The sink pressure was initially set at one quarter the source pressure
so that there was no net octuple.
5.3.2 Tracer transport in a 5-spot conﬁguration
The ﬁve-spot streamlines shown in Figure 5.4 are a result of a source strength of
+4 and sink strengths of -1. When the total source and sink strengths are equal,
the ﬂow is considered to have zero “charge.” In a zero charge ﬂow in a closed
system (zero ﬂux boundary condition) there is no change in volume. We have
modeled the brain as an open system with a zero pressure boundary condition.
Therefore, the boundary of the computational domain is itself a pseudo-source.
As a result, there are streamlines in Figure 5.4 that did not originate from the80
source and there was a loss in total ﬂuid volume from the system. It is diﬃcult to
predict whether this is the appropriate boundary condition for the brain. There
is an endogenous production of interstitial ﬂuid (ISF) that is constantly recycling
through the extracellular space of brain tissue. This might suggest a constant
positive ﬂux of ﬂuid as a boundary condition. It is unknown how ISF production
would respond to withdrawal of large volumes of ﬂuid. If a net loss of ﬂuid volume
proved to be harmful, the relative strengths of the sources and sinks could be
adjusted to maintain a constant ﬂuid volume.
We assumed that tracers initially released at a ﬁnite radius around the point
source follow the streamline that they start on. In the case of a zero net charge
multipole, all of the ﬂuid which emanates from the sources is withdrawn by the
sinks. To check the validity of this assumption we used Koplik’s biased random
walker model to calculate a local Peclet number along each streamline. The upper
panel of Figure 5.4 illustrates the boundary where the local Peclet number is
unity. Inside the boundary, the Peclet number is greater than 1, and we assume
tracer particles do not signiﬁcantly deviate from their streamlines. The three
lines correspond to diﬀusion coeﬃcients of 10−12, 10−11, and 10−10 m2/sec which
represent all classes of therapeutics from small molecules to viral vectors [3, 91, 98].
Molecules with the lowest diﬀusion coeﬃcient (yellow line) were in the convective
regime along nearly all of the possible tracer paths. The exceptions were tracers
released at angles 0◦, 90◦, 180◦, and 270◦ with respect to the x-axis. These tracers
were subject to the low velocity zone surrounding the four stagnation points (two
on the x-axis and two on the y-axis). At moderate diﬀusion coeﬃcients (green
line), only the tracers that have paths close to the line between the source and a
sink were within the convective regime. Finally, at high diﬀusion coeﬃcients (red81
line) the convective regime was limited to the immediate area around the sources
and sinks. A Peclet number less than unity does not indicate that a tracer does
not reach a sink. Rather, a Peclet number of less than unity suggests that a tracer
could “jump” streamlines, so there is an equal probability it will move to a faster
(more direct path) or a slower (more circuitous path) streamline.
The lower panel of Figure 5.4 shows the positions of tracer particles when the
time since infusion equals their half-life for ﬁrst-order elimination constants ranging
from 10−3 to 10−5 s−1. Again, this range was meant to encompass the elimination
constants for many types of molecules in the brain from neurotransmitters to
proteins [3, 26]. We assumed that the local Peclet number is greater than unity and
that all tracer particles stay on their initial streamlines. For molecules with slow
elimination constants (yellow dots), all tracer particles were able to reach sinks in
a time that was less than their half-life except for those tracers stuck at stagnation
points. For molecules with moderate elimination constants (green dots), most
tracers did not get to a sink, but they were able to penetrate a radial distance of
about 5 mm before the elapsed time reached their half-life. Finally, molecules with
fast elimination constants (red dots) were eliminated before penetrating more than
2 mm.
The beneﬁt of a 5-spot conﬁguration with no net charge is that it can contain
molecules of any diﬀusion coeﬃcient or elimination constant to a conﬁned region.
However, as we discovered experimentally, it is diﬃcult to withdraw ﬂuid from a
poroelastic medium under negative pressure. Consequently, the best sink may be
passive, that is a zero pressure point sink. In practice, a sink at ambient pressure
still provides a nominal negative pressure since the intracerebral pressure is approx-
imately 3.8 kPa [99]. We have evaluated a 5-spot conﬁguration with passive sinks82
Figure 5.4: Tracer transport along 5-spot streamlines for an infusion pres-
sure of 30 kPa and withdrawal pressure of 7.5 kPa. Upper: The
local Peclet number is greater than one within the solid lines
for diﬀusion coeﬃcients of 10−12 m2/sec (yellow), 10−11 m2/sec
(green), and 10−10 m2/sec (red). Lower: Tracer particle position
at their half-life for ﬁrst order elimination constants of 10−5 1/sec
(yellow), 10−4 1/sec (green), 10−3 1/sec (red)83
Figure 5.5: Tracer transport along 5-spot streamlines for an infusion pres-
sure of 30 kPa and withdrawal pressure of 3.8 kPa. Upper: The
local Peclet number is greater than one within the solid lines
for diﬀusion coeﬃcients of 10−12 m2/sec (yellow), 10−11 m2/sec
(green), and 10−10 m2/sec (red). Lower: Tracer particle position
at their half-life for ﬁrst order elimination constants of 10−5 1/sec
(yellow), 10−4 1/sec (green), 10−3 1/sec (red)84
where the source has a charge of +8 and the four sinks have a combined charge
of -4. Because there is a net charge of +4, there were no stagnation points, and
some streamlines escape the 5-spot domain. Figure 5.5 reproduces the local Peclet
number regimes and transit times for a passive sink 5-spot conﬁguration with a
pressure source of 30 kPa and pressure sinks of -3.8 kPa. Quantitatively there was
little diﬀerence between ﬁgure 5.4 and 5.5. The convective regime was slightly
larger with passive sinks, but the transit times were almost identical. The notable
exception was the fate of tracer particles with small elimination constants (yellow
dots). Instead of being trapped at stagnation points like in the no net charge
5-spot, in the passive sink case there was the possibility that tracer particles with
long half-lives could escape into surrounding tissue.
The source-sink spacing was set to 5 mm in the above simulations because it
represents a relevant length scale for CED. But in practice it may be more eﬀective
to set the spacing between sources and sinks, and even multiple sources, based on
the elimination mechanisms of a given drug. Figure 5.6 demonstrates the maximum
penetration distance as function of ﬁrst-order elimination constants according to
eq. 5.15. Most chemotherapy drugs and therapeutic proteins have elimination
constants on the order of 10−4 1/sec [3]. Flow rates in animal models tend to be
less than 1 µL/min and ﬂow rates in clinical trials range from 4-6 µL/min [15, 17].
Taking these values to be typical for CED, the distance between sources should be
no more than 1 cm for most drugs. For molecules that are eliminated quickly, such
as neurotransmitters, that source spacing should be closer to 2-3 mm. A lower
bound on elimination is 10−6 1/sec, which is the turnover rate for the interstitial
ﬂuid of the brain [26], suggests source spacing should be no further than 2-4 cm.85
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Figure 5.6: The steady-state penetration distance as a function of the ﬁrst-
order elimination constant according to eq. 5.15 for diﬀerent ﬂow
rates at porosity of 0.2.86
5.3.3 Tracer transport in a stratiﬁed porous medium
The concept of a passive sink was extended to examine the case of a stratiﬁed
porous medium. Figure 5.7 shows the streamlines for stratiﬁed porous medium
with a single source (upper panel) and a dipole (lower panel). The permeability in
the lower half of the domain (red) was 100 times greater than upper half (yellow)
to reﬂect the diﬀerences in permeability between white and gray matter [30]. The
pressure source was set to 30 kPa and located 1 mm away from the boundary
between the two layers. Interestingly, the path of the streamlines between the two
layers is almost symmetric, although the speed in the red layer is 100 times greater
than the speed in the less permeable yellow layer. To achieve a dipole with no net
charge, the source and sink velocity potential must be equal. According to Darcy’s
law, the velocity potential is the product of the pressure and the permeability.
Therefore, the sink strength for the dipole was not -30 kPa, but -0.3 kPa since
the yellow layer is 100 times more permeable. In other words, the multipole ﬂow
ﬁeld is not only a function of the source and sink strengths, but also of the ratio
of permeabilities between dissimilar regions. This result suggest that a passive
sink may be ideally suited for removing ﬂuid from high permeability zones like
white matter and necrotic zones of tumors which are cited as a major cause for
side-eﬀects from CED [24].
5.3.4 Characterization of multipole ﬂows in brain phan-
toms
A ﬁve-spot microﬂuidic probe was fabricated to test the feasibility of conducting
multipole ﬂows in poroelastic mediums like hydrogels and brain tissue. The probe87
Figure 5.7: Streamlines for a stratiﬁed porous medium where the lower half
of the domain has a permeability 100 times greater than the
upper half. Upper: Streamlines for a single source a strength of
30 kPa. Lower: Streamlines for a dipole ﬂow between a source
with strength of 30 kPa and a sink with strength -0.3 kPa.88
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was tested in a stratiﬁed agarose brain phantom (Figure 5.8). Withdrawal of
ﬂuid from a point sink was unsuccessful at negative pressures up to -70 kPa. We
hypothesize that this results from pressure-induced deformation of the gel, which
reduces the permeability of the agarose near the withdrawal probe [37]. As we
presented in chapter 2, the permeability changes with dilation of the medium.
Under negative pressure, the dilation is negative, leading to compression of the gel
at the withdrawal point and a reduction in the permeability.
Although the ﬁve-spot probes proved ineﬀective for multipole ﬂow, they were
utilized in several other experiments with interesting results. Perhaps most use-
ful was the ability to map the permeability of a heterogeneous porous medium as
shown in Figure 5.8. By applying equation 2.19 we were able to distinguish dif-
ferences in permeability between 0.6% and 2% agarose, as well as at the interface
between the two layers.
5.3.5 Characterization of line-sinks in brain phantoms and
in vivo
A line-sink probe was developed to address the diﬃculty of withdrawing ﬂuid from
a point sink (Figure 5.2). The rationale behind the line-sink was that distributing
the stress due to withdrawal along the length of the probe would lead to less com-
pression and would generate measurable withdrawal rates. Withdrawal pressures
of -10 to -70 kPa in 0.6% agarose resulted in ﬂow rates of 0.25 to 2 µL/min. Un-
fortunately, this promising result did not transfer to brain tissue. Line-sink probes
were tested in both the cortex and striatum of adult rats. There was no measurable
withdrawal ﬂow at pressures in the range of -10 to -70 kPa. We hypothesize that
some element of the brain tissue was occluding the 10 µm holes of the line-sink.90
Therefore, we attempted to selectively degrade the major structural component of
the brain ECM, hyaluronan, by infusing 10 µL of hyaluronidase into the striatum
of three animals. After a 24 hour digestion, a line-sink probe was inserted into
the striatum and a negative pressure was applied. Once again, no measurable ﬂow
rates were observed at any withdrawal pressure.
5.4 Discussion
Treatment-associated complications of CED are primarily due to poor control over
the distribution of infused solutions. Successfully applying multipole ﬂows in the
brain could signiﬁcantly improve the eﬀectiveness of CED by controlling the di-
rection of ﬂow ﬁelds and conﬁning infused solutions to speciﬁc tissue regions of
therapeutic interest. Multipole ﬂows on the length and time scales relevant for
CED seem feasible from the results of our simple potential ﬂow model with some
notable exceptions. Molecules with large diﬀusion coeﬃcients such as ions and
neurotransmitters may have local Peclet numbers that are less than one at a dis-
tance as small as 1 mm from the infusion site. This does not necessarily preclude
these molecules from being used multipole ﬂows; it simply implies that the bene-
ﬁts of convection are minimal and transit times could deviate from the expected
values for transport along streamlines. Regardless of the transport mechanism, the
eﬀectiveness of a therapeutic is limited by the elimination mechanisms of a given
molecule. At steady-state, a “standing wave” occurs where the time constant for
elimination and convection are the same. The position of the “standing wave”
dictates the maximum practical spacing between sources and sinks. It further sets
a limit on the volume of tissue that can be treated using a single source. At the
very least, the number of catheters needed to treat a targeted region could be91
calculated with some knowledge of a drug’s clearance rate. This is an important
result that has not been mentioned the clinical literature to date.
While our theoretical model indicates that multipole ﬂow is feasible for CED,
our experimental results suggest more work is needed in order to understand the
mechanics of brain tissue. Mechanical properties of a poroelastic medium may limit
the performance of a combined infusion and withdrawal schemes. If we return to
the poroelastic model developed in Chapter 2 and apply the withdrawal conditions
used in this chapter, we ﬁnd the dilation in agarose to be between -5 and -10.
This negative dilation, or compression, yields a 500 to 4000 times reduction in
permeability. This dramatic drop in permeability predicted by the poroelastic
model could explain our observation of negligible ﬂow rates during withdrawal from
a point source. If we assume that the withdrawal pressure was evenly distributed
between the 20 withdrawal holes on the line sink, then the dilation becomes about -
1 or a reduction of 10 times in the permeability. The prediction of a more moderate
compression from the line-sink qualitatively supports the observable ﬂow rates for
withdrawal from agarose.
Unfortunately, the poroelastic model oﬀers little insight into our observation
during in vivo withdrawals. One reason for this lack of agreement between model
and experiment is that the mechanical properties used in the model are based on
macroscopic tissue samples. It is possible that the bulk mechanical properties are
dominated by mechanics of the cellular components of the tissue and the mechanics
that are important for withdrawal involve the extracellular components. Another
explanation is that the lipid membrane of adjacent cells occludes the withdrawal
ports. However, if it proves impossible to withdraw ﬂuid under negative pressures,
we have shown with our potential ﬂow model that passive sinks may be almost as92
eﬀective at directing the ﬂow ﬁeld. It is unlikely, however, that a microﬂuidic device
would be the best choice for a passive sink because the pressure drop through the
channel is so high compared to a simple catheter.CHAPTER 6
ENHANCED NANOPARTICLE PENETRATION IN THE BRAIN
BY REMODELING OF THE EXTRACELLULAR MATRIX USING
A DUAL CHANNEL MICROFLUIDIC PROBE
6.1 Introduction
Many promising treatments for brain diseases involve nanoparticles as drug or
gene carriers. Here we refer to nanoparticles in the broadest sense, including viral
and non-viral vectors, polymeric drug carriers, and liposomes. The restrictive
nature of the blood-brain barrier makes intracranial infusions an attractive drug
delivery strategy. However, the transport through the extracellular space of tissues
is hindered by the relatively large size of nanoparticles (10-100 nm) compared
to small molecule drugs or therapeutic proteins which easily penetrate the brain
ECM. The transport of nanoparticles may be enhanced by hydraulic and enzymatic
remodeling of the extracellular space.
Viral [100, 101, 102, 65, 66] and non-viral vectors [103] have successfully been in-
fused into normal tissue [101, 65, 66] and animal models of brain tumors [104, 103]
and Parkinson’s disease [100]. Bankiewicz and colleagues infused AAV vectors
into Parkisonian monkeys in conjunction with systemically administered L-dopa
(a pro-drug) resulting in a restoration of dopamine production with minimal side
eﬀects [100]. However, viral vector penetration was impeded by interaction with
the heparin-sulfate proteoglycans on cell surfaces. This binding can be blocked,
and penetration enhanced, by co-infusion with heparin which saturates heparin
binding sites on cell surfaces [101]. The ﬁrst clinical trails of CED mediated gene
therapy used intratumoral infusion of a liposome encapsulated herpes simplex virus
9394
(HSV-1-tk), containing a suicide gene, combined with systemic administration of
ganciclovir into glioblastoma patients [105]. Only two of eight patients saw a signif-
icant reduction in tumor volume, which was attributed to inhomogeneous liposome
distribution in tumors near white matter and necrotic zones. Further study on a
AAV2 vector for HSV-1-tk showed that even with good vector distribution, gene
expression was too low to yield signiﬁcant reduction in tumor volume [104]. These
experiments suggest that convection enhanced delivery of particles ∼100 nm in
size is unreliable using present methods.
Bankiewicz and colleagues studied combining real-time imaging with the CED
of liposomes into animal tumor models [106, 68, 107, 64, 63, 108, 109]. Initial
studies showed that 40 nm liposomes distributed throughout the striatum of rats
[106]. This result is consistent with recent estimates of the eﬀective pore size (38-64
nm) of the extracellular matrix of gray matter [62]. Real-time magnetic resonance
imaging (MRI) was used to monitor liposome distribution into the striatum of
healthy rats and into 9L and C6 tumor rat tumor models [68]. Infusion of lipo-
somes into the heterogeneous C6 tumor model resulted in entrainment of liposomes
into necrotic zones which were detected during infusion, rather than post-mortem
[68]. Real-time MRI was further validated in the primate brain where a linear
relationship was reported between the volume infused and the volume distributed
for infusion of up to 100 µL of 90-110 nm liposomes [107].
Studies of the eﬀects of charge, size, and steric coating suggested that CED
of nanoparticles is possible provided that particles are less that 100 nm in diam-
eter, neutral or negatively charged, and are not subject to fast (k<0.001 min.−1)
elimination mechanisms [64, 65]. Further investigation into the role of tissue aﬃn-
ity on distribution illustrated that hydrophilic and PEGylated molecules have95
higher volumes of distribution over their hydrophobic and charged counterparts
[108]. Nanoparticles tend to accumulate in and move through perivascular spaces
[64, 63, 66]. The perivascular space is thought to play a similar role in removing
ﬂuid from the brain as the lymphatics do in other tissues [52]. In terms of ﬂuid
ﬂow, the perivascular space serves as a high permeability pathway for nanoparti-
cles compared with the dense ECM. It has been suggested that this preferential
transport through the perivascular space is responsible for some the side-eﬀects
reported from CED and gene therapy clinical trials [63].
A possible approach for enhancing nanoparticle penetration through tissue is
selective enzymatic digestion of speciﬁc ECM components. For example, Netti and
colleagues reported a 100% increase in the diﬀusivity of IgG following collagenase
treatment of xenografted tumors [51]. The mechanism of increased diﬀusivity of
IgG was attributed to the collapse of the rigid collagen backbone which stabilizes
and binds to proteoglycans. A correlation was reported between mechanical stiﬀ-
ness and transport resistance, but no such correlation existed between proteoglycan
content and transport resistance. Unlike most other tissues, the extracellular ma-
trix of the brain is unique because it has a low content of ﬁbrous matrix proteins
such as collagen. The brain ECM primarily consists of a family of proteoglycans
called lecticans and the two components to which they bind, tenascins and hyaluro-
nan [110]. Together these three macromolecules form a ternary structure in the
extracellular space of the adult brain [111]. Hyaluronan serves as the structural
backbone of the brain and the highly charged chondroitin-sulphate proteoglycans
(CSPG) side chains anchor the ECM to cells and blood vessels. Hyaluronan and
CSPG can be selectively degraded in the brain by hyaluronidase [112] and chon-
droitinase [113], respectively.96
The eﬀect of digesting ECM components on the physical properties of brain
tissue has not be reported at the time of this writing. But, the brain ECM re-
sembles some of the structural features of cartilage, which has been extensively
studied. Cartilage has high hyaluronan content bound to proteoglycans like the
brain ECM, but also is rich in collagen ﬁbers unlike the brain ECM. Scott and
colleagues found that hyaluronan, rather that collagen or proteoglycans, is respon-
sible for most of the hydraulic resistance in the rabbit synovium [114, 115]. The
digestion of the hyaluronan in rabbit synovium was reported to increase perme-
ability 10 fold [116]. The interaction between hyaluronan and CSPG chains is
necessary to prevent outﬂow of ﬂuid from joints under pressure [117]. The inter-
active eﬀect between hyaluronan and CSPGs is supported by hindered transport
theory for composite hydrogels [118, 44]. Calculations on disordered ﬁbrous media
composed of ﬁbers with two distinct radii showed that the hydraulic permeability
increases for a relatively small concentration of ﬁne ﬁbers [118, 44, 119, 45].
In Chapter 2, we discussed the potential of using tissue dilation to enhance
transport of macromolecule and nanoparticles. Another example of hydraulic re-
modeling is the use of osmotic gradients to draw ﬂuid into or drive ﬂuid out of the
ECM. Osmotic opening of the blood-brain barrier is a common method to grant
access of water soluble drugs, proteins, antibodies, and viral vectors to the brain
[120, 121]. Hyperosmolar solutions can be administered systemically to establish
an osmotic gradient which forces water into blood vessels and out of endothe-
lial cells, leading to a compromise of the tight junctions with adjacent glial cells.
The opposite treatment, infusion of a hyperosmolar solution into the extracellular
space, leads to a water ﬂux out of surrounding blood vessels and cells. As an
example, co-infusion of a hyperosmolar concentration of mannitol enhanced viral97
vector distribution and gene expression in bolus injections of AAV vectors in ani-
mal models for Alzheimer’s disease [122] and Sandhoﬀ disease [123]. Penetration of
liposomes into the striatum of rats during CED was also enhanced by co-infusion
with mannitol [106].
The purpose of this study is to evaluate hydraulic and enzymatic remodeling
of the ECM to enhance the distribution of nanoparticles during CED. A two-
channel microﬂuidic probe was fabricated that is capable of delivering two separate
solutions at the same infusion site. For hydraulic remodeling, one channel delivered
either a buﬀer solution or a hyperosmotic solution of mannitol preceding infusion
of polystyrene nanoparticles through the other channel. Nanoparticles were also
co-infused with mannitol. For enzymatic remodeling, one channel delivered an
enzyme solution followed by infusion of nanoparticles through the other channel.
The ECM was digested for 30 minutes or 24 hours prior to nanoparticle infusion.
The volume of distribution for nanoparticles increased two-fold following 24 hour
digestion of the ECM and for co-infusion with mannitol.
6.2 Materials and Methods
6.2.1 Microﬂuidic probe fabrication
A two channel probe was fabricated using the procedure outlined brieﬂy in Chapter
1 and described in detail in Appendix A. The diﬀerences between the two-channel
probes and the probes from Chapter 1 is number of channels, geometry, and ﬂuidic
connections. The two-channel probe consists of three features; 1) a 6 mm long
shank for insertion into tissue with a cross-sectional area of 100 X 100 µm, 2) a
base with a hole in the middle for fastening the device down to the holder, and98
Table 6.1: Size and zeta potential of polystyrene nanoparticle before and
after incubation in 1% BSA
Stock BSA Treated
20 nm 36 nm (-32 mV) 54 nm (-6 mV)
100 nm 115 nm (-27 mV) 130 nm (-18 mV)
3) two protrusions with cross-sectional areas of 70 X 100 µm for connection with
polyimide tubing.
6.2.2 Preparation of nanoparticles
Carboxylate-modiﬁed monodisperse polystyrene nanoparticles (Molecular Probes,
FluoSpheres) were used as a model system to determine the role of particle size
on penetration. Particles with diameters of 20 nm and 100 nm were chosen as
models of viral vectors and polymeric nanoparticles, respectively. The carboxylate-
modiﬁed surface provides a highly charged and relatively hydrophilic particle com-
pared to bare polystyrene. Non-speciﬁc binding was reduced by incubating a
0.02% solid solution of nanoparticles in 1% bovine serum albumin for four hours
at room temperature. Proteins readily absorb to the surface of the polystyrene
particles via hydrophobic interactions. Particles size was determined by static
light scattering and particle zeta potential by mobility between charged parallel
plates (Brookhaven Instruments Corp., ZetaPlus). Stock solutions of particles (2%
solids) were diluted 10,000X in phosphate buﬀered saline (PBS) for sizing. The
particle diameter and charge particles of both sizes are shown in Table 6.1. It is
unknown whether the discrepancy between the supplier’s quoted size (24 nm) and
the measured size (36 nm) is due to aggregation or manufacturer error. Solutions99
Figure 6.1: Upper: The two channels run parallel to each other along the
shank and have outlets at 0.5 mm from the tip. Lower: Each
channel has its own protrusion for connection to small bore poly-
imide tubing. The device is fastened to a custom holder using a
screw and washer.100
were sonicated in a water bath for 10 minutes prior to sizing, however, aggrega-
tion is possible at such a small size. Incubation with BSA increased the diameter
by 15-18 nm which is in agreement with the reported hydrodynamic diameter of
BSA (7.2 nm) [124]. For brain infusions, nanoparticle solid concentration was held
constant at 0.02% giving approximately 1013 particles/mL for the 20 nm particles
and 1011 particles/mL for the 100 nm particles.
6.2.3 Animal Experiments
Fifty Sprague-Dawley rats (270-305 g) were used in this study. All procedures
were done in accordance with the regulations of the Yale University Institutional
Animal Care and Use Committee. Rats were anesthetized with ketamine (100
mg/kg)/xylyzine (10 mg/kg) solution via intraperitoneal injection. The head was
shaved and disinfected with butadiene/alcohol/butadiene cotton swabs. An inci-
sion was made and a 1.5 mm diameter hole was drilled in the skull 3 mm laterally
from bregma in one or both hemispheres. The probe was inserted to a depth of 5
mm at a rate of 1 mm/sec with a micromanipulator on a stereotactic frame. The
tissue was allowed to equilibrate mechanically for 2 min. An upstream pressure
of 7.5-15 psi was applied to maintain ﬂow rates of 0.5-1 µL/min for infusions of
5-10 µL. Pressures of up to 30 psi were needed for the more viscous 25% mannitol
solutions. Following infusion, probes were left inserted for 2 min. to allow any
excess pressure to dissipate and prevent reﬂux up the insertion cavity.
Control experiments of both particle sizes consisted of a 5 µL infused vol-
ume at 0.75 µL/min into the caudate. In addition, 5 µL/min of Evans Blue la-
beled BSA were infused into the caudate to compare the diﬀerences in distribution
between a molecule that moves through the ECM unhindered and the nanopar-101
ticles. Three pretreatment conditions were considered to enhance nanoparticle
penetration–hydraulic dilation, hyperosmolar dilation, and enzymatic degradation.
Hydraulic dilation consisted of infusing 5 µL of PBS at 1 µL/min through one chan-
nel immediately prior to infusion of 5 µL of nanoparticles at 0.75 µL/min through
the second channel. The same procedure was used with 25% mannitol to induce
dilation by via osmotic gradients. To distinguish hydraulic dilation from osmot-
ically induced dilation we also co-infused mannitol and nanoparticles through a
single channel at a ﬂow rate of 0.75 µL/min.
Enzymatic degradation of the ECM was performed with hyaluronidase (1000
U/mL) or chondroitinase ABC (0.5 U/mL) for 30 minutes followed by nanoparticle
infusion. Five microliters of enzyme solution was infused at 1 µL/min. Results
from these experiments suggested a longer digestion time may be necessary, so we
also performed a 24 hour digestion using hyaluronidase. For the 24 hour digestion,
the probe was removed after enzyme infusion and then reinserted after digestion.
To avoid possible reﬂux through the enzyme infusion site we used a separate in-
fusion site for the nanoparticles. Five microliters of the nanoparticle solution was
infused at 0.75 µL/min. The enzyme infusion site was 3 mm lateral and -0.5 mm
posterior from bregma and the nanoparticle infusion site was 3 mm lateral and 0.5
mm posterior from bregma, both infusions were performed at a depth of 5 mm.
6.2.4 Tissue Analysis
The animals were immediately sacriﬁced by decapitation and the brains were re-
moved and ﬂash frozen on dry ice. The brains were sectioned into 50 µm slices
on a cryostat and imaged on a ﬂuorescent stereoscope (Zeiss Lumar V.12) using
a CY3 ﬁlter. Exposure time was optimized for each brain to achieve maximum102
1 mm
Figure 6.2: Five microliter infusion of BSA (left), 20 nm polystyrene particles
(middle), and 100 nm polystyrene particles (left) into the caudate
of rats.
dynamic range without saturation of any pixels on a CCD camera. The volume of
distribution of the nanoparticles was calculated using the procedure described in
Section 4.2.5. The reﬂux of particles into corpus callosum was not included in the
volume calculation.
6.3 Results
6.3.1 Nanoparticles are entrained in perivascular spaces
Our initial studies on nanoparticle infusion revealed two important diﬀerences
between the distribution of nanoparticles and proteins. First, the transport of
nanoparticles were clearly hindered compared with transport of BSA (Figure 6.2).
The volume of distribution of BSA was approximately 20 mm3, whereas the vol-
ume of distribution of 20 nm and 100 nm particles ranged from 2-5 mm3 (Figure
6.4). Second, the shape of the distribution was diﬀerent for BSA and the parti-
cles. The BSA distribution is roughly spherical and penetrates the entire caudate.
The distribution of nanoparticles has a branched structure indicating that the
particles travel along preferred paths. This structure has been reported for lipo-
some infusions and has been attributed to liposomes accumulating preferentially103
in the perivascular space of large cerebral blood vessels [64]. Another interesting
result was that the diﬀerence between the volumes of distribution for the particles
with diﬀerent diameters was statistically insigniﬁcant. This observation seems to
further support an alternative pathway for nanoparticle transport other than the
through the ECM where penetration is expected to be size dependent. If nanopar-
ticle transport is indeed limited to the perivascular spaces of large vessels, then
it would be diﬃcult to target large tissue regions since only a small percentage of
cells are close to these vessels.
6.3.2 Enzymatic degradation of the extracellular matrix
The dual channel microﬂuidic probe was fabricated to explore methods for enhanc-
ing nanoparticle penetration into the ECM. Our ﬁrst attempt was to selectively
degrade components of the ECM enzymatically. Diﬀusion of 40 kDa dextrans in-
creased by 50% in rat brain slices after a 30 minute digestion with hyaluronidase
[125]. However, we observed little measurable change in penetration or distribution
of nanoparticles after a digestion time of 30 minutes for treatments of hyaluronidase
or chondroitinase (Figure 6.4). Therefore, we considered a longer digestion time
based on reports of complete digestion of hyaluronan after 24 hours [113]. After
a 24 hour digestion with hyaluronidase we observed almost a doubling in the vol-
ume of distribution of 20 nm particles (Figure 6.3). In addition, the shape of the
distribution was more diﬀuse than infusions with no pretreatment, which may be
indicative of penetration into the entire extracellular space rather than just the
perivascular space.104
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Figure 6.3: Upper: The distribution of a 5 µL infusion of 20 nm polystyrene
particles without any pretreatment (left), co-infused with hyper-
osmolar concentration of mannitol (center), and after a 24 hour
digestion of the ECM by hyaluronidase (right). Lower: Volume
of distribution in gray matter for diﬀerent treatments. Error bars
represent one standard deviation for n=3.105
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Figure 6.4: Volume of distribution of a 5 µL infusion 20 nm and 100 nm
particles in gray matter after 30 minute digestion with either
hyaluronidase or chondroitinase. Error bars represent one stan-
dard deviation for n=3.
6.3.3 Hydraulic remodeling of the extracellular matrix
In addition to enzymatic treatments, we also attempted to hydraulically remodel
the ECM. Dilation was induced by infusing PBS or 25% mannitol prior to nanopar-
ticle infusion, or by co-infusion of mannitol with nanoparticles. Both pretreatment
conditions resulted in decreased nanoparticle distribution. The volume of distri-
bution for buﬀer pretreatment was 30% less than control infusions and 50% less
for mannitol pretreatment. One feature that was consistent for all hydraulic pre-
treatments was a high degree of entrainment in the perivascular space around the
medial cerebral artery (MCA) (Figure 6.5). This result suggests that the pretreat-
ment dilated the perivascular space rather than the ECM, so that the nanoparticles
were immediately afterward followed the path of least resistance. All of the pre-
treatment experiments were conducted with the same probe, so it is possible that
technical complications related to the probe insertion were the source of these106
Figure 6.5: Five microliter infusion of 20 nm polystyrene particles immedi-
ately following a pre-infusion of PBS (left) or mannitol (right).
The distribution of nanoparticles for both treatments was highly
localized around the medial cerebral artery (inside red circle).
results. Since the results were ambiguous, further investigation is needed to de-
termine the feasibility of hydraulic pretreatments. In contrast to the mannitol
pretreatment, co-infusion of nanoparticles with mannitol increased distribution a
similar degree as 24 hour hyaluronidase digestion (Figure 6.3).
6.4 Discussion
The endogenous ECM of the brain is the major barrier to transport of nanopar-
ticles in the brain. The eﬀective pore size of the brain has been reported to be
between 20-60 nm [62], which would seem to exclude transport of nanoparticles.
Yet there are several reports of viral vectors and liposomes penetrating over several
millimeters in animal models [64, 100], albeit in a highly branched distribution.
Some researchers have proposed that the perivascular space acts as a conduit for
removing excess ﬂuid and a preferential pathway for nanoparticles [63, 66]. The
branched distribution in our control experiments and the concentration of parti-107
cles in the MCA following hydraulic pretreatments support the perivascular space
theory. If nanoparticles are entrained primarily in the perivascular spaces of large
vessels, as our results suggest, then penetration into an entire targeted region may
not be possible without remodeling the ECM. Our volume of distribution for 56
nm and 130 nm BSA-coated polystyrene particles agrees with the volume of dis-
tribution reported by Chen and colleagues for polystyrene particles under similar
infusion conditions [65].
The goal of remodeling the ECM is to normalize the permeability of the tar-
geted region or to make the region temporarily isotropic. As long as there are
heterogeneities, ﬂuid and particles will follow the path of least resistance. One
normalization strategy is to make the ECM more permeable by selectively degrad-
ing certain components. This study is the ﬁrst report that the authors are aware of
that has considered enzymatic degradation of ECM to enhance nanoparticle pene-
tration. The doubling of the volume of distribution, and perhaps more importantly
the diﬀuse shape of the distribution, seem to indicate we have normalized the ex-
tracellular space around the infusion site. We note that the biological consequence
of degrading the brain ECM in humans is unknown. But, the ECM has been
reported to return to normal twelve days after complete degradation of hyaluro-
nan in the rat cerebrum [112]. Similarly, perineuronal nets were also completely
reconstituted ﬁve months after chondroitinase injections [113].
In brain tumors, transport maybe more or less hindered depending on the
grade of the tumor. In low grade gliomas diﬀusion is reduced because of the high
density of tumor cells which causes a decrease in extracellular space [126]. High
grade gliomas have a higher extracellular void fraction compared to healthy tissue
but overexpression of ECM proteins makes the extracellular space highly tortuous108
[127]. A possible complication with enzymatic degradation of tumors is promoting
metastasis of tumor cells. This potentially disastrous side-eﬀect is certainly plausi-
ble since gliomas express proteinases to degrade native ECM components in order
to inﬁltrate healthy tissue [128]. However, systemically administered hyaluronidase
has improved the outcome of standard chemotherapy [129] and boron neutron cap-
ture therapy for glioblastomas [130].
Hydraulic remodeling via co-infusion of hyperosmolar mannitol was just as ef-
fective as enzymatic treatments for enhancing the penetration of nanoparticles.
Mamot and colleagues reported a 50% increase in distribution volume of 40 nm
liposomes in the rat brain [106], which is similar to the 100% increase we observed
for 54 nm polystyrene particles. The simplicity and short response time to man-
nitol may make it a more attractive strategy than enzymatic degradation. The
permeability eﬀect of hyperosmolar treatments on the blood-brain barrier are re-
versed within 10 minutes and virtually no side-eﬀects been reported for treating
edema with systemic administration of mannitol [121].
Microﬂuidic probes are capable of infusion rates that are relevant for CED
and have some performance advantages due to their small size [49]. This second
generation of probes performed much better than those discussed in Chapter 4.
There was a remarkable lack of backﬂow owing to the custom insertion handle
which provided for much higher insertion quality and repeatability between probes.
Here, we have reported the ﬁrst in vivo infusion of two diﬀerent solutions at
the same infusion site. Although the results of the hydraulic pretreatment were
disappointing from a drug delivery perspective, the insight into the physiological
response to infusion induced edema is notable. Future studies will consider other
infusion parameters such as particle concentration, infusion volume, and infusion109
rate as well as the feasibility of combining ECM remodeling with infusions of
polymeric drug carriers.APPENDIX A
APPENDIX A: DETAILED FABRICATION PROCESS FOR
MICROFLUIDIC PROBES
The fabrication of microﬂuidic probes is a four mask process which uses stan-
dard micromachining techniques. Silicon is used a substrate and rigid carrier for
polymer-based microﬂuidic channels. Channels are formed on a polyimide adhesion
layer via a sacriﬁcial process. The sacriﬁcial layer is photoresist and the structural
layer is parylene. This process requires 300-500 µm double side polished silicon
wafer with <100> crystal orientation.
1. Remove organic residues from wafers with a 30 minute bath in 50 ◦C Nanos-
trip.
2. Immediately before depositing PECVD silicon dioxide dehydrate the wafer
on a 170 ◦C hotplate.
3. The ﬁrst layer to deposit and pattern is the silicon dioxide mask for the
backside deep silicon etch. The selectivity of Si:SiO2 is 150:1 for the 1thru
process on the Unaxis deep silicon etcher. Deposit the appropriate thickness
of silicon dioxide (1.5-3 µm) using the N1.46 undoped oxide recipe on the
GSI PECVD. Make sure the clean cycle is at least 1 minute greater than the
etch cycle.
4. Measure your ﬁlm thickness with optical spectrophotometer.
5. Vapor prime the wafer with a HMDS using the YES oven. This is a 30 minute
process that deposits a monolayer of HMDS which enhances the adhesion be-
tween photoresist and silicon. Good adhesion is especially important for any
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wet etch. However, the HMDS process runs at 150 ◦C, making it incompat-
ible with parylene (Tg=110 ◦C).
6. Spin Shipley 1813 at 4000 rpm on the silicon dioxide side of the wafer and
remove any resist on the other side of the wafer.
7. Soft bake at 115 ◦C for 90 seconds.
8. Expose with a broadband UV source (i.e. EV-620) with a 40 mJ dose
(BACKSIDE mask).
9. Develop for 60 seconds in 300 MIF developer.
10. Hard bake at 115 ◦C for 1 minute.
11. Remove any residual resist or developer with a 100 W oxygen plasma (Glen
1000) for 1 minute.
12. Wet etch the silicon dioxide in 6:1 buﬀered oxide etch for 30 minutes. Make
sure all the oxide is etched using an optical spectrophotometer.
13. Remove the resist mask with acetone/IPA/water rinse followed by a Piranha
clean (Hematech). Alternatively, the resist mask can be left on and used as
an additional mask layer for the backside silicon etch.
14. Use the 1thru process on the Unaxis to etch the backside silicon. Etch to
a depth that leave a 100 µm membrane on the frontside. For example, for
a 300 µm wafer, etch 200 µm. As of March 2006 the etch rate was 0.67
µm/loop or 2.9 µm/min. Note that there will be up to a 5% variation in the
etch depth across the wafer with the edges etching faster than the center.112
The selectivity also varies from about 150:1 to 190:1 from the center to the
edge of the wafer.
15. Deposit 1 µm of N1.46 silicon dioxide (GSI) on the backside of the wafer to
act as the frontside etch stop.
16. Spin Photoneece PWDC-1000 at 4000 rpm on the polyimide spinner using
the 4 inch wafer chuck. Remove resist on the backside with a acetone soaked
Q-tip.
17. Soft bake on a polyimide hotplate at 115 ◦C for 3 minutes.
18. Expose using soft contact lithography (EV-620) at a dose of 250 mJ (FRONT-
SIDE mask).
19. Develop with a 90 second double puddle in 300 MIF.
20. Descum with 400 W oxygen plasma for 1 min (Glen 1000).
21. Cross-link the polyimide (imidization reaction) using recipe 3 on the YES
Polyimide oven.
22. Spin Shipley 1045 straight out of bottle at 1000 rpm. This spin rate will
yield 10-12 µm lines which act as the sacriﬁcial layer for the channels.
23. Soft bake for 30 minutes at 90 ◦C in a convection oven.
24. Expose using soft contact lithography (EV-620) at a dose of 250 mJ (CHAN
mask).
25. Develop with a 2 minute double puddle in 300 MIF. This step removes a large
quantity of resist and it is a good idea to change develop for each wafer.113
26. Remove edge bead with acetone soaked Q-tip.
27. Hard bake at 115 ◦C for 1 minute. This step is important for achieving
sloped sidewalls which are crucial for achieving coverage during electron bead
evaporation of the aluminum mask.
28. Descum and roughen resist with 400 W oxygen plasma for 1 min (Glen 1000).
29. Measure and record channel height and width with proﬁlometer (P-10).
30. Deposit approximately 5 microns (3-4 grams) of Parylene C (SCS PDS-2010).
This will take about 5 hours on the CNF parylene coating system.
31. Roughen the parylene surface with a 100 W oxygen plasma for 30 seconds.
32. Evaporate 100-150 nm of electron beam evaporated metal (SC4500 6 pocket).
Evaporate at a deposition rate of 2-2.5 ˚ A/sec. Increase and decrease power
at about 1%/min. Faster rates will result in cracked crucibles which are
expensive.
33. Apply P-20 liquid primer and allow to sit on wafer surface for at least 10
seconds and then spin at 4000 rpm.
34. Spin Shipley 1045 at 1000 rpm (ramp at 100 rpm/sec) for 45 seconds.
35. Soft bake in a convection oven for 30 minutes at 90 ◦C.
36. Expose using soft contact lithography (EV-620) at a dose of 250 mJ (CHAN-
TOP mask).
37. Develop with a 2 minute double puddle in 300 MIF. This step removes a large
quantity of resist and it is a good idea to change develop for each wafer.114
38. Etch aluminum with wet aluminum etch solution until visually gone and
then add a few minutes (should take about 5 minutes). The wet etch will
undercut the resist mask slightly, so plan for this when laying out the CAD
for this layer.
39. Remove resist mask with acetone/IPA/DI water bath.
40. Spin Shipley 1075 directly out of the bottle in a dynamic spin at 100 rpm/sec
up to 1500 rpm for 45 seconds. Make sure there are no “boulders”or bad“comet
trails” by cleaning the edges and inside of the bottle neck before pouring.
41. Soft bake in a convection oven for 30 minutes at 90 ◦C.
42. Expose using soft contact lithography (EV-620) at a dose of 400 mJ (FRONT-
SIDE mask).
43. Develop with a 90 second double puddle in 300 MIF.
44. Hard bake in a convection oven for 4-12 hours at 90 ◦C.
45. DUV resist cure for 2 minutes.
46. Etch parylene using 150 W oxygen plasma (Oxford 81). The etch rate is
anywhere from 0.19-0.27 µm/min, start with a 20-25 minute etch.
47. Etch residual parylene on the backside of the wafer with a 10-15 minute
oxygen plasma (Oxford 81). Make sure to place wafers on silicon chips so
that the frontside wafer surface does not touch the platen.
48. Remove the edge bead before deep silicon etch and bake resist at 90 ◦C for
another 1-2 hours. You can use the same etch mask for both the frontside115
parylene and silicon etches as long as there is at least 4 µm of resist remaining
after the parylene etch. Check on the P-10 to make sure there is enough resist.
If not, strip resist and repeat 1075 procedure.
49. Use Otrench recipe on the Unaxis 770 to etch frontside silicon. The etch rate
is approximately 0.5 µm/loop or 2-2.5 µm/min.
50. Remove the resist mask with a 20 minute acetone bath, 2 minute 400 W
oxygen plasma, and a second 20 minute acetone bath. There maybe some
residual resist remaining, but that is ﬁne because the ﬁnal parylene etch will
get rid of it.
51. Etch parylene to form channel tops using the aluminum mask using a 150 W
oxygen plasma (Oxford 81) for the same amount of time as the ﬁrst parylene
etch.
52. Remove aluminum mask in wet aluminum etch (can take up to 15 minutes
since the surface in oxidized).
53. Remove silicon dioxide etch stop in 6:1 BOE (10-15 minutes).
54. Clear sacriﬁcial resist from channels in a 4 hour acetone bath followed by 1
hour in IPA and 12 hours in DI water without drying in between baths. This
step is crucial to ensure total dissolution and removal of photoresist. If the
wafer is taken directly from the acetone and dried, resist will crystallize in
the channels and at the inlets and outlets.
55. The macro-micro connection for these devices usually involve gluing some
type of small bore tubing (polyimide or PEEK) or micropipettes to the chan-
nel inlets. The glue of choice for these devices is a two-part epoxy made by116
Miller-Stephenson (Epoxy 907 Adhesive System). The high viscosity of this
epoxy ensures that minimal (<1 mm) glue will be sucked up into tubing by
capillary forces. The “stringy” nature of this epoxy allows one to apply the
glue without actually touching the device/tubing with the applicator. The
applicator used is either a glass pipette or a small dental brush (with brush
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